

Intravitreal Bevacizumab (Avastin) in the Treatment of

Ophthalmology

113, 1695-1705.e6

DOI: [10.1016/j.optha.2006.05.064](https://doi.org/10.1016/j.optha.2006.05.064)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ecancermedalscience. Ecancermedalscience, 2013, 7, 336.	0.6	16
2	A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opinion on Pharmacotherapy, 2006, 7, 2355-2368.	0.9	8
3	Management of diabetic macular edema with antiangiogenic therapy. Expert Review of Ophthalmology, 2007, 2, 23-26.	0.3	0
4	New developments in diabetic retinopathy. Expert Review of Ophthalmology, 2007, 2, 947-956.	0.3	0
5	Exploring the molecular mechanism of ocular angiogenesis inhibition by triamcinolone acetonide. Expert Review of Ophthalmology, 2007, 2, 19-22.	0.3	0
7	Pharmacotherapies for Diabetic Retinopathy: Present and Future. Experimental Diabetes Research, 2007, 2007, 1-8.	3.8	18
8	Contributions of Inflammatory Processes to the Development of the Early Stages of Diabetic Retinopathy. Experimental Diabetes Research, 2007, 2007, 1-14.	3.8	535
9	Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in Exudative Age-Related Macular Degeneration and Diffuse Diabetic Macular Edema. Ophthalmic Research, 2007, 39, 139-142.	1.0	47
11	Role of Intravitreal Bevacizumab in Neovascular Glaucoma. Journal of Ocular Pharmacology and Therapeutics, 2007, 23, 487-491.	0.6	80
12	New pharmacologic approaches to treating diabetic retinopathy. American Journal of Health-System Pharmacy, 2007, 64, S15-S21.	0.5	18
13	Management of Diabetic Retinopathy. JAMA - Journal of the American Medical Association, 2007, 298, 902.	3.8	731
14	Hypoxia-inducible factor expression in human RPE cells. British Journal of Ophthalmology, 2007, 91, 1406-1410.	2.1	68
15	Vascular Endothelial Growth Factor in Aqueous Humor Before and After Intravitreal Injection of Bevacizumab in Eyes With Diabetic Retinopathy. JAMA Ophthalmology, 2007, 125, 1363.	2.6	80
16	STANDARDIZED VISUAL ACUITY RESULTS ASSOCIATED WITH PRIMARY VERSUS SECONDARY BEVACIZUMAB (AVASTIN) TREATMENT FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 701-706.	1.0	39
17	INTRAVITREAL BEVACIZUMAB (AVASTIN) INJECTION ALONE OR COMBINED WITH TRIAMCINOLONE VERSUS MACULAR PHOTOCOAGULATION AS PRIMARY TREATMENT OF DIABETIC MACULAR EDEMA. Retina, 2007, 27, 1187-1195.	1.0	119
18	VISUAL SIDE EFFECTS OF SUCCESSFUL SCATTER LASER PHOTOCOAGULATION SURGERY FOR PROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2007, 27, 816-824.	1.0	149
19	MICROPLASMIN-INDUCED POSTERIOR VITREOUS DETACHMENT AFFECTS VITREOUS OXYGEN LEVELS. Retina, 2007, 27, 1090-1096.	1.0	116
20	INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR RADIATION RETINOPATHY 53 YEARS AFTER TREATMENT OF RETINOBLASTOMA. Retinal Cases and Brief Reports, 2007, 1, 198-201.	0.3	8

#	ARTICLE	IF	CITATIONS
21	Anti-vascular endothelial growth factor therapy for ocular neovascular disease. <i>Current Opinion in Ophthalmology</i> , 2007, 18, 502-508.	1.3	234
22	INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION. <i>Retina</i> , 2007, 27, 419-425.	1.0	234
24	Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy. <i>Yearbook of Ophthalmology</i> , 2007, 2007, 125-126.	0.0	0
25	Pneumatic Retinopexy. <i>Ophthalmology</i> , 2007, 114, 401-402.	2.5	2
27	Pharmacokinetics of Intravitreal Bevacizumab (Avastin). <i>Ophthalmology</i> , 2007, 114, 855-859.	2.5	636
28	Findings in Fluorescein Angiography and Optical Coherence Tomography after Intravitreal Bevacizumab in Type 2 Idiopathic Macular Telangiectasia. <i>Ophthalmology</i> , 2007, 114, 1736-1742.	2.5	99
29	OCT after Retinal Detachment. <i>Ophthalmology</i> , 2007, 114, 2096-2097.	2.5	0
30	Association of Complement Factor H and LOC387715 Genotypes with Response of Exudative Age-Related Macular Degeneration to Intravitreal Bevacizumab. <i>Ophthalmology</i> , 2007, 114, 2168-2173.	2.5	195
31	Pharmacokinetics of Intravitreal Ranibizumab (Lucentis). <i>Ophthalmology</i> , 2007, 114, 2179-2182.	2.5	497
32	Anti-Angiogenic Effects of Ribonucleic Acid Interference Targeting Vascular Endothelial Growth Factor and Hypoxia-Inducible Factor-1 α . <i>American Journal of Ophthalmology</i> , 2007, 144, 761-768.	1.7	45
33	Regression of neovascular posterior capsule vessels by intravitreal bevacizumab. <i>Journal of Cataract and Refractive Surgery</i> , 2007, 33, 1113-1115.	0.7	17
34	Bevacizumab and Retinal Ischemia. <i>Ophthalmology</i> , 2007, 114, 2096-2096.e2.	2.5	39
35	New treatments for age-related macular degeneration. <i>Lancet, The</i> , 2007, 370, 1479-1480.	6.3	8
36	Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1209-1226.	1.9	43
37	21st Century treatment of diabetic retinopathy. <i>Expert Review of Endocrinology and Metabolism</i> , 2007, 2, 623-631.	1.2	3
38	Bevacizumab for Neovascular Ocular Diseases. <i>Annals of Pharmacotherapy</i> , 2007, 41, 614-625.	0.9	156
39	Vitrectomy: when things go wrong. <i>Expert Review of Ophthalmology</i> , 2007, 2, 645-660.	0.3	1
40	Pegaptanib sodium for the treatment of ocular vascular disease. <i>Expert Review of Ophthalmology</i> , 2007, 2, 45-60.	0.3	1

#	ARTICLE	IF	CITATIONS
41	Bevacizumab: a word of caution. <i>Canadian Journal of Ophthalmology</i> , 2007, 42, 760-761.	0.4	2
42	Combined photodynamic therapy and intravitreal triamcinolone injection for choroidal neovascularization in Best disease. <i>Canadian Journal of Ophthalmology</i> , 2007, 42, 761-762.	0.4	8
43	The effects of the subconjunctival injection of bevacizumab (Avastin®) on angiogenesis in the rat cornea. <i>Anais Da Academia Brasileira De Ciencias</i> , 2007, 79, 389-394.	0.3	58
44	Trials That Matter: Two Faces of Progress in the Treatment of Age-Related Macular Degeneration. <i>Annals of Internal Medicine</i> , 2007, 146, 532.	2.0	9
45	Intravitreal injection: balancing the risks. <i>Eye</i> , 2007, 21, 313-316.	1.1	7
46	Intravitreal VEGF-inhibitors: is Avastin® a generic substitute for Lucentis®?. <i>Acta Ophthalmologica</i> , 2007, 85, 2-4.	0.4	17
47	Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin®,) injections. <i>Acta Ophthalmologica</i> , 2007, 85, 689-690.	0.4	31
48	Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. <i>Acta Ophthalmologica</i> , 2008, 86, 322-328.	0.6	147
49	Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. <i>Clinical and Experimental Ophthalmology</i> , 2007, 35, 745-748.	1.3	71
50	Neovascular glaucoma. <i>Progress in Retinal and Eye Research</i> , 2007, 26, 470-485.	7.3	194
52	Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurity. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 1727-1730.	1.0	148
53	Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin®). <i>International Ophthalmology</i> , 2008, 28, 425-427.	0.6	17
54	Immunological mechanisms in the pathogenesis of diabetic retinopathy. <i>Seminars in Immunopathology</i> , 2008, 30, 65-84.	2.8	296
56	Intravitreal anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. <i>Diabetologia</i> , 2008, 51, 1574-1580.	2.9	188
58	Intravitreal injection of bevacizumab to treat neovascular glaucoma. <i>Japanese Journal of Ophthalmology</i> , 2008, 52, 410-412.	0.9	5
59	Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2008, 246, 837-842.	1.0	162
60	Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2008, 246, 1379-1381.	1.0	30
61	Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2008, 246, 1699-1705.	1.0	125

#	ARTICLE	IF	CITATIONS
62	Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. <i>Journal of Cellular Physiology</i> , 2008, 217, 13-22.	2.0	59
63	Intravitreal bevacizumab (Avastin [®]) for radiation retinopathy neovascularization. <i>Acta Ophthalmologica</i> , 2008, 86, 115-116.	0.6	15
64	Intravitreal bevacizumab (Avastin [®]) in proliferative diabetic retinopathy. <i>Acta Ophthalmologica</i> , 2008, 86, 683-687.	0.6	55
65	Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). <i>Acta Ophthalmologica</i> , 2008, 86, 385-389.	0.6	113
66	Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. <i>Acta Ophthalmologica</i> , 2008, 86, 365-371.	0.6	62
67	Complications in patients after intravitreal injection of bevacizumab. <i>Acta Ophthalmologica</i> , 2008, 86, 372-376.	0.6	179
68	Intravitreal bevacizumab for vitreous haemorrhage. <i>Acta Ophthalmologica</i> , 2008, 86, 585-586.	0.6	17
69	Geographic atrophy and choroidal melanoma located 3mm apart. <i>Acta Ophthalmologica</i> , 2008, 86, 584-585.	0.6	0
70	Progression of diabetic tractional retinal detachment following single injection of intravitreal Avastin. <i>Eye</i> , 2008, 22, 862-862.	1.1	19
71	Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. <i>Eye</i> , 2008, 22, 1168-1171.	1.1	32
72	Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. <i>Clinical and Experimental Ophthalmology</i> , 2008, 36, 449-454.	1.3	31
73	Diabetic retinopathy and systemic vascular complications. <i>Progress in Retinal and Eye Research</i> , 2008, 27, 161-176.	7.3	187
74	Regulation of retinal blood flow in health and disease. <i>Progress in Retinal and Eye Research</i> , 2008, 27, 284-330.	7.3	493
75	Vascular endothelial growth factor in eye disease. <i>Progress in Retinal and Eye Research</i> , 2008, 27, 331-371.	7.3	607
76	Diabetic retinopathy: A comprehensive review. <i>Indian Journal of Medical Sciences</i> , 2008, 62, 500.	0.1	52
77	Comparative Therapy Evaluation of Intravitreal Bevacizumab and Triamcinolone Acetonide on Persistent Diffuse Diabetic Macular Edema. <i>American Journal of Ophthalmology</i> , 2008, 145, 854-861.e3.	1.7	170
78	Bevacizumab Pretreatment and Long-acting Gas Infusion on Vitreous Clear-up After Diabetic Vitrectomy. <i>American Journal of Ophthalmology</i> , 2008, 146, 211-217.e1.	1.7	76
79	The Effect of Topical Bevacizumab on Corneal Neovascularization. <i>Ophthalmology</i> , 2008, 115, e33-e38.	2.5	200

#	ARTICLE	IF	CITATIONS
80	Intravitreal Bevacizumab to Treat Iris Neovascularization and Neovascular Glaucoma Secondary to Ischemic Retinal Diseases in 41 Consecutive Cases. <i>Ophthalmology</i> , 2008, 115, 1571-1580.e3.	2.5	200
81	Drug-induced ocular side effects. , 2008, , 45-287.		0
82	Protocolo de detección y seguimiento de la retinopatía diabética. <i>Medicine</i> , 2008, 10, 1169-1174.	0.0	0
83	Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. <i>Acta Ophthalmologica</i> , 2008, 86, 800-805.	0.6	49
84	Shall we use Avastin [®] or Lucentis [®] for ocular neovascularization?. <i>Acta Ophthalmologica</i> , 2008, 86, 352-355.	0.6	6
86	Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. <i>British Journal of Ophthalmology</i> , 2008, 92, 1450-1455.	2.1	147
87	Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. <i>British Journal of Ophthalmology</i> , 2008, 92, 213-216.	2.1	364
88	Efficacy of intravitreal bevacizumab as adjunctive treatment with pars plana vitrectomy, endolaser photocoagulation, and trabeculectomy for neovascular glaucoma. <i>British Journal of Ophthalmology</i> , 2008, 92, 1431-1433.	2.1	23
89	Interventions for diabetic macular oedema: a systematic review of the literature. <i>British Journal of Ophthalmology</i> , 2008, 92, 1581-1590.	2.1	38
90	Pharmacotherapy for the Treatment of Choroidal Neovascularization Due to Age-Related Macular Degeneration. <i>Annual Review of Pharmacology and Toxicology</i> , 2008, 48, 61-78.	4.2	34
91	Iluvien [®] : a new sustained delivery technology for posterior eye disease. <i>Expert Opinion on Drug Delivery</i> , 2008, 5, 1039-1046.	2.4	137
92	Effects of Photocoagulation on Intraretinal P ₂ in Cat. , 2008, 49, 380.		52
93	Suprachoroidal fluid as a complication of 23-gauge vitreous surgery. <i>British Journal of Ophthalmology</i> , 2008, 92, 1433-1434.	2.1	21
95	Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. <i>British Journal of Ophthalmology</i> , 2008, 92, 1606-1611.	2.1	120
96	Autofluorescence and OCT features of Bietti's crystalline dystrophy. <i>British Journal of Ophthalmology</i> , 2008, 92, 718-720.	2.1	22
97	Retinal detachment with macular hole following intravitreal bevacizumab in patient with severe proliferative diabetic retinopathy. <i>British Journal of Ophthalmology</i> , 2008, 92, 717-718.	2.1	19
98	Effects of Bevacizumab (Avastin) on Retinal Cells in Organotypic Culture. , 2008, 49, 3164.		38
99	Comparison of Bevacizumab, Ranibizumab, and Pegaptanib In Vitro: Efficiency and Possible Additional Pathways. , 2008, 49, 4523.		167

#	ARTICLE	IF	CITATIONS
100	TEM7 (PLXDC1) in Neovascular Endothelial Cells of Fibrovascular Membranes from Patients with Proliferative Diabetic Retinopathy. , 2008, 49, 3151.		42
102	Emerging drugs for diabetic retinopathy. Expert Opinion on Emerging Drugs, 2008, 13, 675-694.	1.0	29
104	OFF-LABEL USE OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR SALVAGE TREATMENT IN PROGRESSIVE THRESHOLD RETINOPATHY OF PREMATURITY. Retina, 2008, 28, S13-S18.	1.0	126
105	LONG-TERM EFFECT OF INTRAVITREAL BEVACIZUMAB (AVASTIN) IN PATIENTS WITH CHRONIC DIFFUSE DIABETIC MACULAR EDEMA. Retina, 2008, 28, 1053-1060.	1.0	152
106	INCIDENCE OF ACUTE ONSET ENDOPHTHALMITIS FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) INJECTION. Retina, 2008, 28, 564-567.	1.0	145
107	BEVACIZUMAB (AVASTIN) DOES NOT HARM RETINAL FUNCTION AFTER INTRAVITREAL INJECTION AS SHOWN BY ELECTRORETINOGRAPHY IN ADULT MICE. Retina, 2008, 28, 46-55.	1.0	40
108	Subconjunctival Bevacizumab for Corneal Neovascularization. Cornea, 2008, 27, 992-995.	0.9	74
109	Diagnostic and Therapeutic Challenges. Retina, 2008, 28, 1357-1360.	1.0	1
110	INTRAVITREAL BEVACIZUMAB (AVASTIN) PREVENTION OF PANRETINAL PHOTOCOAGULATION-INDUCED COMPLICATIONS IN PATIENTS WITH SEVERE PROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2008, 28, 1319-1324.	1.0	45
111	Periocular Triamcinolone Enhances Intraocular Gene Expression after Delivery by Adenovirus. , 2008, 49, 399.		5
112	Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany. Clinical Ophthalmology, 2008, 2, 253.	0.9	10
113	Aspectos atuais na fisiopatologia do edema macular diab�tico. Revista Brasileira De Oftalmologia, 2008, 67, 45-49.	0.1	2
114	Current and future approaches in the prevention and treatment of diabetic retinopathy. Clinical Ophthalmology, 2008, 2, 425.	0.9	5
115	Update on the Treatment of Diabetic Retinopathy. Scientific World Journal, The, 2008, 8, 98-120.	0.8	32
116	Bevacizumab-Augmented Retinal Laser Photocoagulation in Proliferative Diabetic Retinopathy: A Randomized Double-Masked Clinical Trial. European Journal of Ophthalmology, 2008, 18, 263-269.	0.7	116
117	Intravitreal Bevacizumab versus Combined Bevacizumab-Triamcinolone versus Macular Laser Photocoagulation in Diabetic Macular Edema. European Journal of Ophthalmology, 2008, 18, 941-948.	0.7	91
118	Incomplete Posterior Hyaloid Detachment after Intravitreal Pegaptanib Injection in Diabetic Macular Edema. European Journal of Ophthalmology, 2008, 18, 469-472.	0.7	9
119	Posterior capsule opacification and neovascularization treated with intravitreal bevacizumab and Nd:YAG capsulotomy. Clinical Ophthalmology, 2008, 2, 657.	0.9	4

#	ARTICLE	IF	CITATIONS
120	Intravitreal Bevacizumab Injection for Macular Edema Secondary to Branch Retinal Vein Occlusion. Journal of Korean Ophthalmological Society, 2009, 50, 1800.	0.0	3
121	Therapeutic Effects of Intravitreal Bevacizumab Injection for Retinal Neovascularization Secondary to Proliferative Diabetic Retinopathy. Journal of Korean Ophthalmological Society, 2009, 50, 1359.	0.0	1
123	Tractional Retinal Detachment After Intravitreal Bevacizumab (Avastin®) Injection in Proliferative Diabetic Retinopathy. Journal of Korean Ophthalmological Society, 2009, 50, 1751.	0.0	2
125	Intravitreal Bevacizumab as an Adjunct Treatment for Neovascular Glaucoma. European Journal of Ophthalmology, 2009, 19, 607-612.	0.7	21
126	Can an Intraoperative Bevacizumab Injection Prevent Recurrent Postvitrectomy Diabetic Vitreous Hemorrhage?. European Journal of Ophthalmology, 2009, 19, 618-621.	0.7	31
127	Effects of an Intravitreal Bevacizumab Injection Combined With Panretinal Photocoagulation on High-Risk Proliferative Diabetic Retinopathy. Korean Journal of Ophthalmology: KJO, 2009, 23, 266.	0.5	22
128	Intravitreal Bevacizumab for the Treatment of Neovascular Glaucoma Associated With Central Retinal Artery Occlusion. Korean Journal of Ophthalmology: KJO, 2009, 23, 215.	0.5	9
129	Anti-angiogenic Drugs as an Adjunctive Therapy in the Surgical Treatment of Diabetic Retinopathy. Current Diabetes Reviews, 2009, 5, 52-56.	0.6	16
130	Surgical management of cataract and glaucoma. , 2009, , 491-507.		0
131	Intravitreal Bevacizumab for Diabetic Retinopathy. Current Diabetes Reviews, 2009, 5, 39-46.	0.6	58
132	rAAV.sFlt-1 Gene Therapy Achieves Lasting Reversal of Retinal Neovascularization in the Absence of a Strong Immune Response to the Viral Vector. , 2009, 50, 4279.		43
133	Safety Profile of Topical VEGF Neutralization at the Cornea. , 2009, 50, 2095.		64
134	Treatment of retinal diseases with VEGF antagonists. Progress in Brain Research, 2009, 175, 253-267.	0.9	43
135	Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). British Journal of Ophthalmology, 2009, 93, 688-691.	2.1	79
136	Neovascular Glaucoma: A Historical Perspective on Modulating Angiogenesis. Seminars in Ophthalmology, 2009, 24, 106-112.	0.8	5
137	The Effect of Intravitreal Ranibizumab on the Fellow Untreated Eye with Subfoveal Scarring due to Exudative Age-Related Macular Degeneration. Ophthalmologica, 2009, 223, 383-389.	1.0	30
138	Pharmacologic Vitreodynamics and Molecular Flux. Developments in Ophthalmology, 2009, 44, 31-36.	0.1	11
139	Review of Anti-VEGF Therapy in Proliferative Diabetic Retinopathy. Seminars in Ophthalmology, 2009, 24, 87-92.	0.8	82

#	ARTICLE	IF	CITATIONS
140	Bevacizumab (Avastin) in Ocular Processes Other Than Choroidal Neovascularization. <i>Ocular Immunology and Inflammation</i> , 2009, 17, 109-117.	1.0	5
141	Cysteine-rich 61, a Member of the CCN Family, as a Factor Involved in the Pathogenesis of Proliferative Diabetic Retinopathy. , 2009, 50, 3447.		35
142	Therapeutic monoclonal antibodies in ophthalmology. <i>Progress in Retinal and Eye Research</i> , 2009, 28, 117-144.	7.3	144
143	Diabetic Retinopathy: Current Management and Experimental Therapeutic Targets. <i>Pharmacotherapy</i> , 2009, 29, 182-192.	1.2	47
144	Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide). <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 35-42.	1.0	19
145	Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 735-743.	1.0	83
146	Changes in choriocapillaris fenestration of rat eyes after intravitreal bevacizumab injection. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 1089-1094.	1.0	52
147	Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. <i>Japanese Journal of Ophthalmology</i> , 2009, 53, 243-248.	0.9	36
148	Intracameral bevacizumab and mitomycin C Trabeculectomy for eyes with neovascular glaucoma: a case series. <i>Journal of Ocular Biology, Diseases, and Informatics</i> , 2009, 2, 40-46.	0.2	4
150	Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up. <i>Eye</i> , 2009, 23, 117-123.	1.1	109
151	Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. <i>Eye</i> , 2009, 23, 108-111.	1.1	108
152	Bilateral improvement of persistent diffuse diabetic macular oedema after unilateral intravitreal bevacizumab (Avastin) injection. <i>Eye</i> , 2009, 23, 1229-1229.	1.1	15
153	Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage?. <i>Eye</i> , 2009, 23, 1698-1701.	1.1	45
154	Bevacizumab (Avastin) as a surgical adjunct in diabetic vitrectomy for fibrovascular disease. <i>Eye</i> , 2009, 23, 742-743.	1.1	9
155	Should Avastin be used to treat age-related macular degeneration in the NHS? " No. <i>Eye</i> , 2009, 23, 1250-1253.	1.1	4
156	Cardiovascular Risk and Antiangiogenic Therapy for Age-related Macular Degeneration. <i>Survey of Ophthalmology</i> , 2009, 54, 339-348.	1.7	47
157	Bevacizumab (Avastin) for the Treatment of Ocular Disease. <i>Survey of Ophthalmology</i> , 2009, 54, 372-400.	1.7	125
158	Microincision Vitrectomy Surgery and Intravitreal Bevacizumab as a Surgical Adjunct to Treat Diabetic Traction Retinal Detachment. <i>Ophthalmology</i> , 2009, 116, 927-938.	2.5	163

#	ARTICLE	IF	CITATIONS
159	Vitreous Mediators after Intravitreal Bevacizumab or Triamcinolone Acetonide in Eyes with Proliferative Diabetic Retinopathy. <i>Ophthalmology</i> , 2009, 116, 921-926.	2.5	75
160	Randomized Trial of Intravitreal Bevacizumab Alone or Combined with Triamcinolone versus Macular Photocoagulation in Diabetic Macular Edema. <i>Ophthalmology</i> , 2009, 116, 1142-1150.	2.5	203
161	Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema. <i>Ophthalmology</i> , 2009, 116, 1488-1497.e1.	2.5	125
163	Intravitreal Bevacizumab for Prevention of Early Postvitrectomy Hemorrhage in Diabetic PatientsA Randomized Clinical Trial. <i>Ophthalmology</i> , 2009, 116, 1943-1948.	2.5	144
164	Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema. <i>Journal of AAPOS</i> , 2009, 13, 400-402.	0.2	52
165	Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: Promise and concern. <i>Journal of AAPOS</i> , 2009, 13, 329-331.	0.2	32
166	Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy. <i>Journal of Cataract and Refractive Surgery</i> , 2009, 35, 18-25.	0.7	61
167	Central Retinal Sensitivity After Intravitreal Injection of Bevacizumab for Myopic Choroidal Neovascularization. <i>American Journal of Ophthalmology</i> , 2009, 147, 816-824.e1.	1.7	40
168	Intravitreal Bevacizumab for Diabetic Macular Edema Associated With Severe Capillary Loss: One-Year Results of a Pilot Study. <i>American Journal of Ophthalmology</i> , 2009, 147, 1022-1030.e5.	1.7	37
169	Off-Label Use of Bevacizumab for the Treatment of Age-Related Macular Degeneration. <i>Drugs and Aging</i> , 2009, 26, 295-320.	1.3	27
170	Topical Bevacizumab in the Treatment of Corneal Neovascularization. <i>JAMA Ophthalmology</i> , 2009, 127, 381.	2.6	182
171	Pharmacokinetics of Bevacizumab after Topical, Subconjunctival, and Intravitreal Administration in Rabbits. , 2009, 50, 4807.		239
172	Intravitreal Bevacizumab (Avastin) Injection in Retinitis Pigmentosa. <i>Current Eye Research</i> , 2009, 34, 231-237.	0.7	49
173	Effect of Intracameral Bevacizumab Injection on Corneal Endothelial Cells: An <i>In Vivo</i> Evaluation. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2009, 25, 513-518.	0.6	19
174	Rapid progression of subclinical age-related macular degeneration in the untreated fellow eye after intravitreal bevacizumab. <i>Acta Ophthalmologica</i> , 2009, 87, 685-687.	0.6	7
175	Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. <i>Acta Ophthalmologica</i> , 2009, 87, 736-740.	0.6	26
176	Early loss of pregnancy after intravitreal bevacizumab injection. <i>Acta Ophthalmologica</i> , 2010, 88, e136.	0.6	74
179	BEVACIZUMAB IS NOT TOXIC TO RETINAL GANGLION CELLS AFTER REPEATED INTRAVITREAL INJECTION. <i>Retina</i> , 2009, 29, 306-312.	1.0	24

#	ARTICLE	IF	CITATIONS
180	PREPARATION, CHARACTERIZATION, AND IN VIVO EVALUATION OF NANOLIPOSOMES-ENCAPSULATED BEVACIZUMAB (AVASTIN) FOR INTRAVITREAL ADMINISTRATION. <i>Retina</i> , 2009, 29, 699-703.	1.0	150
181	Subconjunctival and Intracorneal Bevacizumab Injection for Corneal Neovascularization in Lipid Keratopathy. <i>Cornea</i> , 2009, 28, 1070-1073.	0.9	40
182	Bevacizumab for the Treatment of Corneal Neovascularization. <i>Cornea</i> , 2009, 28, S26-S30.	0.9	2
183	SAFETY OF REPEAT INTRAVITREAL INJECTIONS OF BEVACIZUMAB VERSUS RANIBIZUMAB. <i>Retina</i> , 2009, 29, 313-318.	1.0	114
184	VISUAL OUTCOMES AND INCIDENCE OF RECURRENT VITREOUS HEMORRHAGE AFTER VITRECTOMY IN DIABETIC EYES PRETREATED WITH BEVACIZUMAB (AVASTIN). <i>Retina</i> , 2009, 29, 926-931.	1.0	58
185	Anti-VEGF Therapy in Proliferative Diabetic Retinopathy. <i>International Ophthalmology Clinics</i> , 2009, 49, 95-107.	0.3	30
186	ORAL TRANSMUCOSAL FENTANYL CITRATE. <i>Retina</i> , 2009, 29, 1506-1512.	1.0	3
187	BEVACIZUMAB PRETREATMENT IN VITRECTOMY WITH SILICONE OIL FOR SEVERE DIABETIC RETINOPATHY. <i>Retina</i> , 2009, 29, 768-774.	1.0	76
188	EFFECTS OF INTRAVITREAL BEVACIZUMAB IN REPEATED DOSES. <i>Retina</i> , 2009, 29, 1346-1355.	1.0	12
189	TRACTIONAL RETINAL DETACHMENT AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB IN PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retinal Cases and Brief Reports</i> , 2009, 3, 70-73.	0.3	27
190	Current Approaches to Retinopathy as a Predictor of Cardiovascular Risk. <i>Frontiers in Diabetes</i> , 2009, , 203-219.	0.4	5
192	Suppression and Regression of Choroidal Neovascularization by the Multitargeted Kinase Inhibitor Pazopanib. <i>JAMA Ophthalmology</i> , 2009, 127, 494.	2.6	76
193	Balance between Pigment Epithelium-Derived Factor and Vascular Endothelial Growth Factor in Diabetic Retinopathy. <i>Frontiers in Diabetes</i> , 2009, , 124-141.	0.4	1
194	Diabetic Traction Retinal Detachment. <i>International Ophthalmology Clinics</i> , 2009, 49, 153-165.	0.3	8
195	Diabetic Retinopathy in Pregnancy. <i>Current Diabetes Reviews</i> , 2009, 5, 151-156.	0.6	13
196	CONCENTRATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN AQUEOUS HUMOR OF EYES WITH ADVANCED RETINOPATHY OF PREMATURITY BEFORE AND AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB. <i>Retina</i> , 2009, 29, 579-585.	1.0	45
197	INTRAVITREAL BEVACIZUMAB AND PANRETINAL PHOTOCOAGULATION FOR PROLIFERATIVE DIABETIC RETINOPATHY ASSOCIATED WITH VITREOUS HEMORRHAGE. <i>Retina</i> , 2009, 29, 1134-1140.	1.0	52
198	STERILE ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB OBTAINED FROM A SINGLE BATCH. <i>Retina</i> , 2010, 30, 485-490.	1.0	58

#	ARTICLE	IF	CITATIONS
199	FIBROUS MEMBRANES IN DIABETIC RETINOPATHY AND BEVACIZUMAB. <i>Retina</i> , 2010, 30, 1012-1016.	1.0	13
200	SPONTANEOUS RESOLUTION OF TOTAL RETINAL DETACHMENT IN COATS DISEASE. <i>Retinal Cases and Brief Reports</i> , 2010, 4, 206-209.	0.3	3
201	HISTOLOGY OF FIBROVASCULAR MEMBRANES OF PROLIFERATIVE DIABETIC RETINOPATHY AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB. <i>Retina</i> , 2010, 30, 468-472.	1.0	20
202	COMPARISON OF CLINICAL OUTCOMES BETWEEN 23-GAUGE AND 20-GAUGE VITRECTOMY IN PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2010, 30, 1662-1670.	1.0	49
203	INTRAVITREAL BEVACIZUMAB DURING PREGNANCY. <i>Retina</i> , 2010, 30, 1405-1411.	1.0	83
204	DOSE OF INTRAVITREAL BEVACIZUMAB (AVASTIN) USED AS PREOPERATIVE ADJUNCT THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2010, 30, 761-764.	1.0	40
205	INTRAVITREAL BEVACIZUMAB AND/OR MACULAR PHOTOCOAGULATION AS A PRIMARY TREATMENT FOR DIFFUSE DIABETIC MACULAR EDEMA. <i>Retina</i> , 2010, 30, 1638-1645.	1.0	57
206	Use of 532-nm Pulsed Potassium Titanyl Phosphate Laser and Adjuvant Intralesional Bevacizumab for Aggressive Respiratory Papillomatosis in Children. <i>JAMA Otolaryngology</i> , 2010, 136, 561.	1.5	51
209	Effect of multiple injections of small divided doses vs single injection of intravitreal bevacizumab on retinal neovascular model in rabbits. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 457-466.	1.0	9
210	Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 641-650.	1.0	35
211	Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 785-791.	1.0	96
212	A review of clinical trials of anti-VEGF agents for diabetic retinopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 915-930.	1.0	238
213	Individualised treatment of proliferative diabetic retinopathy: optimal surgical timing improves long-term outcomes. <i>EPMA Journal</i> , 2010, 1, 78-81.	3.3	9
214	Role of intravitreal bevacizumab in the management of Eales's disease. <i>International Ophthalmology</i> , 2010, 30, 57-61.	0.6	25
215	Intravitreal bevacizumab to facilitate vitrectomy in idiopathic ischaemic retinal vasculitis. <i>International Ophthalmology</i> , 2010, 30, 415-419.	0.6	1
216	Intravitreal bevacizumab for persistent macular edema with proliferative diabetic retinopathy. <i>International Ophthalmology</i> , 2010, 30, 697-702.	0.6	12
217	Silver nano "A" trove for retinal therapies. <i>Journal of Controlled Release</i> , 2010, 145, 76-90.	4.8	98
218	Protein delivery for retinal diseases: From basic considerations to clinical applications. <i>Progress in Retinal and Eye Research</i> , 2010, 29, 443-465.	7.3	83

#	ARTICLE	IF	CITATIONS
219	Effect of an intravitreal injection of bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats. <i>Clinical and Experimental Ophthalmology</i> , 2010, 38, 875-884.	1.3	15
220	Surgical management of the late complications of proliferative diabetic retinopathy. <i>Eye</i> , 2010, 24, 441-449.	1.1	77
221	<i>Serratia marcescens</i> endophthalmitis associated with intravitreal injections of bevacizumab. <i>Eye</i> , 2010, 24, 226-232.	1.1	36
222	Ultrastructure of Rapidly Proliferating Preretinal Membrane of Very Extensive Ischemic Diabetic Retinopathy. <i>Journal of Korean Ophthalmological Society</i> , 2010, 51, 1504.	0.0	0
223	Comparison of Intravitreal Triamcinolone Versus Bevacizumab in Bilateral Diabetic Macular Edema by Optical Coherence Tomography (OCT) Patterns. <i>Journal of Korean Ophthalmological Society</i> , 2010, 51, 210.	0.0	3
224	Long-Term Tolerability and Serum Concentration of Bevacizumab (Avastin) when Injected in Newborn Rabbit Eyes. , 2010, 51, 3701.		34
225	Antifibrotic Activity of Bevacizumab on Human Tenon's Fibroblasts In Vitro. , 2010, 51, 6524.		68
226	Argon Laser Photocoagulation Combined With Subconjunctival and Intravitreal Bevacizumab Injections for a Retrocorneal Neovascular Membrane. <i>Journal of Korean Ophthalmological Society</i> , 2010, 51, 292.	0.0	0
227	Subconjunctival Bevacizumab as an Adjunct to Trabeculectomy in Eyes with Refractory Glaucoma: A Case Series. <i>Korean Journal of Ophthalmology: KJO</i> , 2010, 24, 47.	0.5	24
228	Comprehensive review of the effects of diabetes on ocular health. <i>Expert Review of Ophthalmology</i> , 2010, 5, 557-577.	0.3	71
229	REBOUND NEOVASCULARIZATION DURING BEVACIZUMAB THERAPY. <i>Retinal Cases and Brief Reports</i> , 2010, 4, 216-219.	0.3	1
230	Increased Vitreous Shedding of Microparticles in Proliferative Diabetic Retinopathy Stimulates Endothelial Proliferation. <i>Diabetes</i> , 2010, 59, 694-701.	0.3	65
231	Features of Optical Coherence Tomography Are Predictive of Visual Outcomes after Intravitreal Bevacizumab Injection for Diabetic Macular Edema. <i>Ophthalmologica</i> , 2010, 224, 374-380.	1.0	41
232	Mini Drug Pump for Ophthalmic Use. <i>Current Eye Research</i> , 2010, 35, 192-201.	0.7	58
233	Aqueous Humor Concentration of Bevacizumab After Subconjunctival Injection in Rabbit. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2010, 26, 49-54.	0.6	18
234	Lack of Therapeutic Effect of Ranibizumab in Fellow Eyes After Intravitreal Administration. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2010, 26, 213-216.	0.6	24
235	Neovascularization in diabetic retinopathy. , 2010, , 514-518.		1
236	Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. <i>British Journal of Ophthalmology</i> , 2010, 94, 1215-1218.	2.1	129

#	ARTICLE	IF	CITATIONS
237	Antivascular Endothelial Growth Factor in Diabetic Retinopathy. <i>Developments in Ophthalmology</i> , 2010, 46, 39-53.	0.1	19
238	Retinal heparanase expression in streptozotocin-induced diabetic rats. <i>Canadian Journal of Ophthalmology</i> , 2010, 45, 46-51.	0.4	13
240	Gene Expression Profile of Hyperoxic and Hypoxic Retinas in a Mouse Model of Oxygen-Induced Retinopathy. , 2010, 51, 4307.		66
241	Immediate changes in intraocular pressure after an intravitreal injection of 2.5mg of bevacizumab. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2010, 85, 364-369.	0.1	4
243	Severe Intraocular Inflammation after Intravitreal Injection of Bevacizumab. <i>Ophthalmology</i> , 2010, 117, 512-516.e2.	2.5	68
244	Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients Treated in the MARINA and ANCHOR Trials. <i>American Journal of Ophthalmology</i> , 2010, 149, 939-946.e1.	1.7	69
245	Clinical Factors Related to Recurrence of Anterior Segment Neovascularization After Treatment Including Intravitreal Bevacizumab. <i>American Journal of Ophthalmology</i> , 2010, 149, 964-972.e1.	1.7	34
246	Histopathology of Neovascular Tissue From Eyes With Proliferative Diabetic Retinopathy After Intravitreal Bevacizumab Injection. <i>American Journal of Ophthalmology</i> , 2010, 150, 223-229.e1.	1.7	56
247	Reducing the incidence of early postoperative vitreous haemorrhage by preoperative intravitreal bevacizumab in vitrectomy for diabetic tractional retinal detachment. <i>Acta Ophthalmologica</i> , 2010, 88, 635-640.	0.6	29
248	Combined intravitreal bevacizumab and argon laser treatment for Coats's disease. <i>Acta Ophthalmologica</i> , 2010, 88, e48-9.	0.6	22
249	Intravitreal bevacizumab (Avastin®) in idiopathic retinitis, vasculitis, aneurysms and neuroretinitis. <i>Acta Ophthalmologica</i> , 2010, 88, e40-1.	0.6	24
250	Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma. <i>Acta Ophthalmologica</i> , 2010, 88, 96-102.	0.6	80
251	Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization. <i>Acta Ophthalmologica</i> , 2010, 88, e305-10.	0.6	9
252	Testing toxicity of multiple intravitreal injections of bevacizumab in rabbit eyes. <i>Canadian Journal of Ophthalmology</i> , 2010, 45, 386-392.	0.4	19
253	Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary. <i>Canadian Journal of Ophthalmology</i> , 2010, 45, 501-508.	0.4	8
254	Effects of Pegaptanib Sodium on Retinal Function in Isolated Perfused Vertebrate Retina. <i>Current Eye Research</i> , 2010, 35, 248-254.	0.7	5
255	Pharmacokinetics of Bevacizumab and Its Effect on Vascular Endothelial Growth Factor after Intravitreal Injection of Bevacizumab in Macaque Eyes. , 2010, 51, 1606.		114
256	The Effect of Intravitreal Injection of Bevacizumab on Retinal Circulation in Patients with Neovascular Macular Degeneration. , 2011, 52, 7400.		38

#	ARTICLE	IF	CITATIONS
257	A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. <i>Current Medical Research and Opinion</i> , 2011, 27, 1465-1475.	0.9	91
258	Changes in Aqueous Concentrations of Various Cytokines After Intravitreal Triamcinolone Versus Bevacizumab for Diabetic Macular Edema. <i>American Journal of Ophthalmology</i> , 2011, 152, 686-694.	1.7	247
259	Emerging Evidence Concerning Systemic Safety of Anti-VEGF Agents – Should Ophthalmologists Be Concerned?. <i>American Journal of Ophthalmology</i> , 2011, 152, 329-331.	1.7	59
260	Decreased angiogenin concentration in vitreous and serum in proliferative diabetic retinopathy. <i>Microvascular Research</i> , 2011, 82, 1-5.	1.1	20
261	Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease. <i>Survey of Ophthalmology</i> , 2011, 56, 95-113.	1.7	257
262	Effects and Complications of Bevacizumab Use in Patients with Retinopathy of Prematurity: A Multicenter Study in Taiwan. <i>Ophthalmology</i> , 2011, 118, 176-183.	2.5	141
263	Preoperative Intravitreal Bevacizumab Use as an Adjuvant to Diabetic Vitrectomy: Histopathologic Findings and Clinical Implications. <i>Ophthalmology</i> , 2011, 118, 636-641.	2.5	68
264	The Effect of Adjunctive Intravitreal Bevacizumab for Preventing Postvitrectomy Hemorrhage in Proliferative Diabetic Retinopathy. <i>Ophthalmology</i> , 2011, 118, 2218-2226.	2.5	90
265	Retinopathy of Prematurity in the Time of Bevacizumab: Incorporating the BEAT-ROP Results into Clinical Practice. <i>Ophthalmology</i> , 2011, 118, 1227-1228.	2.5	76
266	Diabetic retinopathy – An update. <i>Saudi Journal of Ophthalmology</i> , 2011, 25, 99-111.	0.3	58
267	Repeated intravitreal bevacizumab (Avastin [®]) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. <i>Acta Ophthalmologica</i> , 2011, 89, 76-81.	0.6	36
268	Descending doses of intravitreal bevacizumab for the regression of diabetic neovascularization. <i>Acta Ophthalmologica</i> , 2011, 89, 218-221.	0.6	9
269	Intravitreal bevacizumab injection for recurrent vitreous haemorrhage after diabetic vitrectomy. <i>Acta Ophthalmologica</i> , 2011, 89, 634-640.	0.6	16
270	Treatment of diabetic retinopathy with anti-VEGF drugs. <i>Acta Ophthalmologica</i> , 2011, 89, 203-207.	0.6	62
271	Treatment of proliferative diabetic retinopathy with anti-VEGF agents. <i>Acta Ophthalmologica</i> , 2011, 89, 405-411.	0.6	89
272	Decreased prothrombin time after intravitreal bevacizumab in the early period in patients with proliferative diabetic retinopathy. <i>Acta Ophthalmologica</i> , 2011, 89, e332-5.	0.6	5
273	Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. <i>Acta Ophthalmologica</i> , 2011, 89, e567-e572.	0.6	58
274	Antiangiogenic drugs and advanced proliferative diabetic retinopathy. <i>Arquivos Brasileiros De Oftalmologia</i> , 2011, 74, 143-146.	0.2	7

#	ARTICLE	IF	CITATIONS
275	Effect of Intravitreal Bevacizumab on Vascular Endothelial Growth Factor Expression in Patients with Proliferative Diabetic Retinopathy. <i>Yonsei Medical Journal</i> , 2011, 52, 151.	0.9	15
276	Retro-mode imaging of fibrovascular membrane in proliferative diabetic retinopathy after intravitreal bevacizumab injection. <i>Clinical Ophthalmology</i> , 2011, 5, 897.	0.9	7
277	Effect of 23-gauge Sutureless Vitrectomy & Preoperative Bevacizumab on Results of Diabetic Vitrectomy. <i>Journal of Korean Ophthalmological Society</i> , 2011, 52, 285.	0.0	0
278	Prophylactic Effects of a Fixed Dorsolamide/Timolol Combination on IOP Elevation before Intravitreal Anti-VEGF Injection. <i>Journal of Korean Ophthalmological Society</i> , 2011, 52, 702.	0.0	1
279	Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture. <i>Journal of Ophthalmology</i> , 2011, 2011, 1-13.	0.6	44
280	Diagnostic and Therapeutic Challenges. <i>Retina</i> , 2011, 31, 994-997.	1.0	0
281	Combined Use of Subconjunctival and Intracorneal Bevacizumab Injection for Corneal Neovascularization. <i>Cornea</i> , 2011, 30, 1110-1114.	0.9	36
282	CHANGES IN AREAS OF CAPILLARY NONPERFUSION AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB IN EYES WITH BRANCH RETINAL VEIN OCCLUSION. <i>Retina</i> , 2011, 31, 1068-1074.	1.0	34
283	A SYSTEMATIC REVIEW OF THE ADVERSE EVENTS OF INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS. <i>Retina</i> , 2011, 31, 1449-1469.	1.0	131
284	Intravitreal Anti-VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery. <i>Current Diabetes Reviews</i> , 2011, 7, 176-184.	0.6	18
286	On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2011, 100, 1523-1527.	0.7	80
287	Solution Formulation Development of a VEGF Inhibitor for Intravitreal Injection. <i>AAPS PharmSciTech</i> , 2011, 12, 362-371.	1.5	8
288	Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 1295-1301.	1.0	14
289	Negative correlation between aqueous vascular endothelial growth factor levels and axial length. <i>Japanese Journal of Ophthalmology</i> , 2011, 55, 401-404.	0.9	35
290	Microvascular Modifications in Diabetic Retinopathy. <i>Current Diabetes Reports</i> , 2011, 11, 253-264.	1.7	170
292	Effects of Intravitreally Injected Bevacizumab on Vascular Endothelial Growth Factor in Fellow Eyes. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2011, 27, 379-383.	0.6	27
293	Vascular endothelial growth factor inhibition in uveitis: a systematic review. <i>British Journal of Ophthalmology</i> , 2011, 95, 162-165.	2.1	45
294	Anti-Vascular Endothelial Growth Factor Agents for Pediatric Retinal Diseases. <i>International Ophthalmology Clinics</i> , 2011, 51, 185-199.	0.3	8

#	ARTICLE	IF	CITATIONS
295	Corneal Penetration of Topical and Subconjunctival Bevacizumab. , 2011, 52, 8718.		111
296	Plasmin Treatment Accelerates Vascular Endothelial Growth Factor Clearance from Rabbit Eyes. , 2011, 52, 6162.		6
297	Retinopathy of Prematurity: Do We Still Have a Problem?. JAMA Ophthalmology, 2011, 129, 1083.	2.6	30
298	Bevacizumab (Avastin) as an Adjunct to Vitrectomy in the Management of Severe Proliferative Diabetic Retinopathy: A Prospective Case Series. Ophthalmic Research, 2011, 45, 23-30.	1.0	14
299	AN INTRAVENOUS MICRODOSE OF BEVACIZUMAB FOR THE TREATMENT OF PIGMENT EPITHELIAL DETACHMENT ASSOCIATED TO AGE-RELATED MACULAR DEGENERATION REFRACTORY TO INTRAVITREAL BEVACIZUMAB: A CASE REPORT. Retinal Cases and Brief Reports, 2011, 5, 290-293.	0.3	0
300	Activation of Endothelial Roundabout Receptor 4 Reduces the Severity of Virus-Induced Keratitis. Journal of Immunology, 2011, 186, 7195-7204.	0.4	16
301	Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration. Current Vascular Pharmacology, 2011, 9, 629-646.	0.8	39
302	The effect of intravitreal ranibizumab on intraoperative bleeding during pars plana vitrectomy for diabetic traction retinal detachment. British Journal of Ophthalmology, 2011, 95, 1337-1339.	2.1	6
303	A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. British Journal of Ophthalmology, 2011, 95, 1216-1222.	2.1	81
304	Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits. Clinical Ophthalmology, 2011, 5, 697.	0.9	75
305	Combined intravitreal bevacizumab with phacoemulsification in visually significant cataract and visually significant exudative maculopathy. Oman Journal of Ophthalmology, 2011, 4, 10.	0.2	1
306	Avastin Treatment Reduces Retinal Neovascularization in a Mouse Model of Retinopathy of Prematurity. Current Eye Research, 2012, 37, 624-629.	0.7	18
307	Diabetic Retinopathy Management. ESASO Course Series, 2012, , 1-34.	0.1	1
308	Managing bevacizumab-induced intraocular inflammation. Indian Journal of Ophthalmology, 2012, 60, 311.	0.5	6
309	Antiangiogenic Therapy for Ischemic Retinopathies. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006411-a006411.	2.9	63
310	Proliferative Diabetic Retinopathy: Laser Treatment and Intravitreal Medication. ESASO Course Series, 2012, , 58-64.	0.1	0
311	Complications and Management of Diabetic Vitrectomy. ESASO Course Series, 2012, , 69-80.	0.1	0
312	Angiofibrotic Response to Vascular Endothelial Growth Factor Inhibition in Diabetic Retinal Detachment. JAMA Ophthalmology, 2012, 130, 1127.	2.6	47

#	ARTICLE	IF	CITATIONS
313	Vascular damage of retina in diabetic retinopathy and its treatment. Expert Review of Ophthalmology, 2012, 7, 73-86.	0.3	0
314	Electrophysiological Assessment of Optic Nerve and Retinal Functions Following Intravitreal Injection of Bevacizumab (Avastin). Journal of Ocular Pharmacology and Therapeutics, 2012, 28, 159-165.	0.6	10
315	A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. British Journal of Ophthalmology, 2012, 96, 587-590.	2.1	129
316	Effect of Vitrectomy on Aqueous VEGF Concentration and Pharmacokinetics of Bevacizumab in Macaque Monkeys. , 2012, 53, 5877.		86
317	Ocular Blood Flow in Diabetes: Contribution to the Microvascular Lesions of Diabetic Retinopathy. , 2012, , 365-387.		0
318	Does Ranibizumab (Lucentis®) Change Retrobulbar Blood Flow in Patients with Neovascular Age-Related Macular Degeneration?. Ophthalmic Research, 2012, 47, 141-145.	1.0	10
319	Lasers in Dermatology and Medicine. , 2012, , .		15
320	Anti-VEGF Treatment of Diabetic Retinopathy. Current Drug Therapy, 2012, 7, 96-100.	0.2	0
321	ELEVATION OF ANGIOGENIC FACTOR CYSTEINE-RICH 61 LEVELS IN VITREOUS OF PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2012, 32, 103-111.	1.0	13
323	EFFECT OF INTRAVITREAL BEVACIZUMAB ON RETROBULBAR BLOOD FLOW IN INJECTED AND UNINJECTED FELLOW EYES OF PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2012, 32, 967-971.	1.0	30
324	Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal?. Current Medical Research and Opinion, 2012, 28, 395-400.	0.9	6
325	Relationship between compliance with ophthalmic examinations preoperatively and visual outcome after vitrectomy for proliferative diabetic retinopathy. Japanese Journal of Ophthalmology, 2012, 56, 481-487.	0.9	4
326	Vascular Endothelial Growth Factor in Plasma and Vitreous Fluid of Patients with Proliferative Diabetic Retinopathy Patients after Intravitreal Injection of Bevacizumab. American Journal of Ophthalmology, 2012, 153, 307-313.e2.	1.7	49
327	Corneal Neovascularization and the Utility of Topical VEGF Inhibition: Ranibizumab (Lucentis) Vs Bevacizumab (Avastin). Ocular Surface, 2012, 10, 67-83.	2.2	138
328	The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology. Mayo Clinic Proceedings, 2012, 87, 77-88.	1.4	162
329	Ocular Pharmacokinetics of Bevacizumab in Vitrectomized Eyes with Silicone Oil Tamponade. , 2012, 53, 5221.		40
330	Phacoemulsification with Intravitreal Bevacizumab Injection in Patients with Cataract and Coexisting Diabetic Retinopathy: Prospective Randomized Study. Journal of Ocular Pharmacology and Therapeutics, 2012, 28, 212-218.	0.6	16
331	Vascular endothelial growth factors in retinal and choroidal neovascular diseases. Annals of Medicine, 2012, 44, 1-17.	1.5	46

#	ARTICLE	IF	CITATIONS
332	Serum Concentrations of Bevacizumab (Avastin) and Vascular Endothelial Growth Factor in Infants With Retinopathy of Prematurity. American Journal of Ophthalmology, 2012, 153, 327-333.e1.	1.7	295
333	Succinate Increases in the Vitreous Fluid of Patients With Active Proliferative Diabetic Retinopathy. American Journal of Ophthalmology, 2012, 153, 896-902.e1.	1.7	18
334	Diabetic Retinopathy and Age-Related Macular Degeneration in the U.S. American Journal of Preventive Medicine, 2012, 43, 48-54.	1.6	40
335	Bevacizumab (Avastin) for retinopathy of prematurity: Wrong dose, wrong drug, or both?. Journal of AAPOS, 2012, 16, 2-4.	0.2	46
336	Inhibition of pathological retinal angiogenesis by the integrin $\alpha_5\beta_1$ antagonist tetraiodothyroacetic acid (tetrac). Experimental Eye Research, 2012, 94, 41-48.	1.2	48
337	Antiangiogenic and antivascular effects of a recombinant tumstatin-derived peptide in a corneal neovascularization model. Biochimie, 2012, 94, 1368-1375.	1.3	7
338	Retinal Not Systemic Oxidative and Inflammatory Stress Correlated with VEGF Expression in Rodent Models of Insulin Resistance and Diabetes. , 2012, 53, 8424.		46
339	Eye Complications of Diabetes. , 2012, , 249-275.		1
340	MEMS-enabled implantable drug infusion pumps for laboratory animal research, preclinical, and clinical applications. Advanced Drug Delivery Reviews, 2012, 64, 1628-1638.	6.6	70
341	Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy. Journal of Diabetes and Its Complications, 2012, 26, 435-441.	1.2	67
342	Short-Term Topical Bevacizumab in the Treatment of Stable Corneal Neovascularization. American Journal of Ophthalmology, 2012, 154, 940-948.e1.	1.7	44
343	<i>In Vivo</i> , <i>In Vitro</i> Toxicity and <i>In Vitro</i> Angiogenic Inhibition of Sunitinib Malate. Current Eye Research, 2012, 37, 567-574.	0.7	20
344	Oxygen Sensing in Retinal Health and Disease. Ophthalmologica, 2012, 227, 115-131.	1.0	68
345	Vascular Complications and Diabetes: Current Therapies and Future Challenges. Journal of Ophthalmology, 2012, 2012, 1-14.	0.6	43
346	Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. Journal of Ophthalmology, 2012, 2012, 1-11.	0.6	43
347	Controlled Release of Bevacizumab Through Nanospheres for Extended Treatment of Age-Related Macular Degeneration. Open Ophthalmology Journal, 2012, 6, 54-58.	0.1	87
348	Acute Visual Loss after Intravitreal Bevacizumab Injection in a Patient with Ocular Ischemic Syndrome. Journal of Korean Ophthalmological Society, 2012, 53, 1893.	0.0	1
349	Diabetic Microangiopathy - Etiopathogenesis, New Possibilities in Diagnostics and Management. , 2012, , .		2

#	ARTICLE	IF	CITATIONS
350	In Vitro Effects of Bevacizumab Treatment on Newborn Rat Retinal Cell Proliferation, Death, and Differentiation. , 2012, 53, 7904.		15
351	Vision, Retinal Thickness, and Foveal Avascular Zone Size After Intravitreal Bevacizumab for Diabetic Macular Edema. <i>Advances in Therapy</i> , 2012, 29, 359-369.	1.3	23
352	Secondary rhegmatogenous retinal detachment following intravitreal bevacizumab in patients with vitreous hemorrhage or tractional retinal detachment secondary to Eales's disease. <i>Graefes's Archive for Clinical and Experimental Ophthalmology</i> , 2012, 250, 685-690.	1.0	19
353	Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans. <i>Acta Ophthalmologica</i> , 2012, 90, 68-70.	0.6	29
354	Combination therapy in diabetic macular oedema and retinal vein occlusion " past and present. <i>Acta Ophthalmologica</i> , 2012, 90, 580-589.	0.6	25
355	Comparison of the use of 5-fluorouracil and bevacizumab in primary trabeculectomy: results at 1-year. <i>Clinical and Experimental Ophthalmology</i> , 2012, 40, e135-42.	1.3	35
356	Disruption of the association of integrin-associated protein (IAP) with tyrosine phosphatase non-receptor type substrate-1 (SHPS)-1 inhibits pathophysiological changes in retinal endothelial function in a rat model of diabetes. <i>Diabetologia</i> , 2012, 55, 835-844.	2.9	13
358	Are monoclonal antibodies a safe treatment for cancer during pregnancy?. <i>Immunotherapy</i> , 2013, 5, 733-741.	1.0	33
359	Incidence of Choroidal Neovascularization in the Fellow Eye in the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2013, 120, 2035-2041.	2.5	81
360	Acute bacterial endophthalmitis after intravitreal bevacizumab injection: Case report and literature review. <i>Saudi Journal of Ophthalmology</i> , 2013, 27, 55-57.	0.3	6
361	Compositions, Formulation, Pharmacology, Pharmacokinetics, and Toxicity of Topical, Periocular, and Intravitreal Ophthalmic Drugs. <i>Methods in Pharmacology and Toxicology</i> , 2013, , 91-118.	0.1	6
362	Surgery for Proliferative Diabetic Retinopathy. , 2013, , 1876-1901.		0
363	Use of Adjuvant Intralesional Bevacizumab for Aggressive Respiratory Papillomatosis in Children. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2013, 139, 496.	1.2	57
364	Can Intravitreal Ranibizumab Alter Retrobulbar Circulation in Eyes with Age-Related Macular Degeneration?. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2013, 29, 723-727.	0.6	3
365	Degree of Decrease in Central Retinal Thickness Predicts Visual Acuity Response to Intravitreal Ranibizumab in Diabetic Macular Edema. <i>Ophthalmologica</i> , 2014, 231, 16-22.	1.0	16
366	Pathophysiology and treatment of diabetic retinopathy. <i>Acta Diabetologica</i> , 2013, 50, 1-20.	1.2	132
367	Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection. <i>Experimental Eye Research</i> , 2013, 110, 50-54.	1.2	32
368	Microvascular complications and diabetic retinopathy: recent advances and future implications. <i>Future Medicinal Chemistry</i> , 2013, 5, 301-314.	1.1	67

#	ARTICLE	IF	CITATIONS
369	Pregnancy-associated Retinal Diseases and Their Management. <i>Survey of Ophthalmology</i> , 2013, 58, 127-142.	1.7	102
370	Recent Advances in the Management of Neovascular Glaucoma. <i>Seminars in Ophthalmology</i> , 2013, 28, 165-172.	0.8	43
371	An Updated Study of the Use of Bevacizumab in the Treatment of Patients with Prethreshold Retinopathy of Prematurity in Taiwan. <i>American Journal of Ophthalmology</i> , 2013, 155, 150-158.e1.	1.7	116
372	Are we there yet? Bevacizumab therapy for retinopathy of prematurity. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2013, 98, F170-F174.	1.4	100
375	Bevacizumab as an adjunct to vitreoretinal surgery for diabetic retinopathy in East Africa. <i>Eye</i> , 2013, 27, 1263-1268.	1.1	13
376	Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation. <i>Eye</i> , 2013, 27, 1391-1396.	1.1	26
377	Primary effects of intravitreal bevacizumab in patients with diabetic macular edema. <i>Pakistan Journal of Medical Sciences</i> , 2013, 29, 1018-22.	0.3	5
378	Intravitreal Avastin as an adjunct in patients with proliferative diabetic retinopathy undergoing pars plana vitrectomy. <i>Pakistan Journal of Medical Sciences</i> , 2013, 29, 590-2.	0.3	13
379	Exploratory Analysis of the Effect of Intravitreal Ranibizumab or Triamcinolone on Worsening of Diabetic Retinopathy in a Randomized Clinical Trial. <i>JAMA Ophthalmology</i> , 2013, 131, 1033.	1.4	99
380	Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, S38-S42.	0.2	37
381	Efficacy of Intravitreal Bevacizumab With Panretinal Photocoagulation Followed by Ahmed Valve Implantation in Neovascular Glaucoma. <i>Journal of Glaucoma</i> , 2013, 22, 768-772.	0.8	44
382	Imaging of Vascular Wall Fine Structure in the Human Retina Using Adaptive Optics Scanning Laser Ophthalmoscopy. , 2013, 54, 7115.		98
383	Identification of VEGF-Independent Cytokines in Proliferative Diabetic Retinopathy Vitreous. , 2013, 54, 6472.		61
384	Influence of Preoperative Intravitreal Bevacizumab on Visual Function in Eyes with Proliferative Diabetic Retinopathy. <i>Ophthalmic Research</i> , 2013, 49, 30-36.	1.0	11
385	Pathophysiology of Diabetic Retinopathy. <i>ISRN Ophthalmology</i> , 2013, 2013, 1-13.	1.7	333
386	Proliferative Diabetic Retinopathy. , 2013, , 969-1000.		5
387	Effect of Dorzolamide/Timolol or Brinzolamide/Timolol Prophylaxis on Intravitreal Anti-VEGF Injection-Induced Intraocular Hypertension. <i>Seminars in Ophthalmology</i> , 2013, 28, 61-67.	0.8	14
388	Vascular Endothelial Growth Factor Gene Polymorphisms and Vitreous Proteome Changes in Diabetic Retinopathy. <i>Seminars in Ophthalmology</i> , 2013, 28, 347-354.	0.8	3

#	ARTICLE	IF	CITATIONS
389	Comparison of the Effect of Unilateral Intravitreal Bevacizumab and Ranibizumab Injection on Diabetic Macular Edema of the Fellow Eye. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2013, 29, 728-732.	0.6	41
390	Intravitreal Bevacizumab (Avastin) and Panretinal Photocoagulation in the Treatment of High-Risk Proliferative Diabetic Retinopathy. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2013, 29, 550-555.	0.6	46
391	Effect of Bevacizumab Injection before Vitrectomy on Intravitreal Hemorrhage in Pseudophakic Patients with Proliferative Diabetic Retinopathy. <i>Ophthalmology and Eye Diseases</i> , 2013, 5, OED.S12352.	1.2	10
392	ALTERED VASCULAR MICROENVIRONMENT BY BEVACIZUMAB IN DIABETIC FIBROVASCULAR MEMBRANE. <i>Retina</i> , 2013, 33, 957-963.	1.0	25
393	INTRAVITREAL BEVACIZUMAB IN THE TREATMENT OF DIABETIC OCULAR NEOVASCULARIZATION. <i>Retina</i> , 2013, 33, 748-755.	1.0	15
394	Topical Ranibizumab as a Treatment of Corneal Neovascularization. <i>Cornea</i> , 2013, 32, 992-997.	0.9	76
395	THE EFFECTS OF AFLIBERCEPT ON THE VIABILITY AND METABOLISM OF OCULAR CELLS IN VITRO. <i>Retina</i> , 2013, 33, 1056-1061.	1.0	24
396	Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization. <i>Journal of Personalized Medicine</i> , 2013, 3, 40-69.	1.1	23
397	Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia. <i>Clinical Ophthalmology</i> , 2013, 7, 1357.	0.9	10
398	A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction. <i>Clinical Ophthalmology</i> , 2013, 7, 621.	0.9	3
399	Thrombocytopenia after Intravitreal Bevacizumab Injection for Macular Edema in Branch Retinal Vein Occlusion. <i>Journal of Korean Ophthalmological Society</i> , 2013, 54, 1788.	0.0	1
400	Emerging roles for antiangiogenesis factors in management of ocular disease. <i>Clinical Ophthalmology</i> , 2013, 6, 533.	0.9	17
401	Tratamiento de la retinopatía del prematuro con bevacizumab intravítreo. <i>Revista Chilena De Pediatría</i> , 2013, 84, 300-307.	0.4	1
402	Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics. <i>Current Drug Metabolism</i> , 2013, 14, 764-790.	0.7	44
403	A Case of Acute Anterior Uveitis Associated with HLA-B27 Positivity after Intravitreal Injection of Bevacizumab. <i>Journal of Korean Ophthalmological Society</i> , 2013, 54, 1945.	0.0	0
404	Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients Treated for Age-Related Macular Degeneration. <i>Journal of Korean Ophthalmological Society</i> , 2013, 54, 1534.	0.0	1
405	Intravitreal Bevacizumab Injection for Serous Retinal Detachment Associated with Leber's Idiopathic Stellate Neuroretinitis. <i>Journal of Korean Ophthalmological Society</i> , 2014, 55, 1562.	0.0	1
406	Intravitreal Injection of Normal Saline Induces Retinal Degeneration in the C57BL/6J Mouse. <i>Translational Vision Science and Technology</i> , 2014, 3, 3.	1.1	33

#	ARTICLE	IF	CITATIONS
407	Changes in the Retinal Vascular Network Morphology (Diameter and Tortuosity) after Administration of Intravitreal Bevacizumab in a Patient with Ischaemic Branch Retinal Vein Occlusion. Case Reports in Ophthalmology, 2014, 5, 411-415.	0.3	4
408	Identification of Chemokines and Growth Factors in Proliferative Diabetic Retinopathy Vitreous. BioMed Research International, 2014, 2014, 1-9.	0.9	34
409	Outcomes of Vitrectomy for Severe Vitreous Hemorrhage of Unknown Etiology. Journal of Korean Ophthalmological Society, 2014, 55, 1024.	0.0	1
410	CEACAM1 Confers Resistance Toward Oxygen-Induced Vessel Damage in a Mouse Model of Retinopathy of Prematurity. Investigative Ophthalmology and Visual Science, 2014, 55, 7950-7960.	3.3	7
411	Perfluorocarbon in vitreoretinal surgery and preoperative bevacizumab in diabetic tractional retinal detachment. World Journal of Diabetes, 2014, 5, 724.	1.3	5
412	Serum Concentration of Vascular Endothelial Growth Factor after Bilateral Intravitreal Injection of Bevacizumab. Korean Journal of Ophthalmology: KJO, 2014, 28, 32.	0.5	12
413	Effectiveness of intravitreal injection of Bevacizumab (Avastin) in the treatment of diabetic macular edema.. Pakistan Journal of Medical Sciences, 2014, 30, 1383-7.	0.3	0
414	Biocompatible Reverse Thermal Gel Sustains the Release of Intravitreal Bevacizumab In Vivo. , 2014, 55, 469.		77
416	Vascular Endothelial Growth Factor Modulates the Function of the Retinal Pigment Epithelium In Vivo. , 2014, 55, 2269.		23
417	Intravitreal Anti-VEGF Treatment as Adjunctive Treatment in the Management of Diabetic Retinopathy. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 303-303.	0.6	0
418	Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema. Eye, 2014, 28, 646-653.	1.1	58
420	What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?. British Journal of Ophthalmology, 2014, 98, i7-i10.	2.1	65
421	Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. The Cochrane Library, 2014, , CD008721.	1.5	43
422	Emergency department visits after intravitreal bevacizumab and ranibizumab injections in diabetic patients. Canadian Journal of Ophthalmology, 2014, 49, e146-e148.	0.4	0
423	Anterior Retinal Cryotherapy and Intravitreal Injection of Bevacizumab in the Treatment of Nonclearing Vitreous Hemorrhage in Proliferative Diabetic Retinopathy. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 353-358.	0.6	5
424	Pharmacotherapy for Treatment and Prevention of Proliferative Diabetic Retinopathy. Current Ophthalmology Reports, 2014, 2, 175-183.	0.5	0
425	Current Management of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy. International Ophthalmology Clinics, 2014, 54, 141-153.	0.3	46
426	Bevacizumab Reduces Neurocan Content and Gene Expression in Newborn Rat Retina In Vitro. , 2014, 55, 5109.		6

#	ARTICLE	IF	CITATIONS
427	RANIBIZUMAB IN PREPROLIFERATIVE (ISCHEMIC) CENTRAL RETINAL VEIN OCCLUSION. <i>Retina</i> , 2014, 34, 1728-1735.	1.0	89
428	Eye Care Availability and Access Among Individuals With Diabetes, Diabetic Retinopathy, or Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2014, 132, 471.	1.4	43
429	Investigating the association between angiogenic cytokines and corneal neovascularization in sulfur mustard intoxicated subjects 26 years after exposure. <i>Toxicology International</i> , 2014, 21, 300.	0.1	7
430	Effects of Subconjunctival Tocilizumab Versus Bevacizumab in Treatment of Corneal Neovascularization in Rabbits. <i>Cornea</i> , 2014, 33, 1088-1094.	0.9	16
431	Paired responses to intravitreal bevacizumab in diabetic macular edema: predictors of response in the fellow eye. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 207-211.	1.0	6
432	In situ covalently cross-linked PEG hydrogel for ocular drug delivery applications. <i>International Journal of Pharmaceutics</i> , 2014, 470, 151-157.	2.6	93
433	A review of anti-VEGF agents for proliferative diabetic retinopathy. <i>Eye</i> , 2014, 28, 510-520.	1.1	200
434	Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 375-391.	1.3	21
435	TWEAK/Fn14 Pathway Is a Novel Mediator of Retinal Neovascularization. , 2014, 55, 801.		27
436	Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. <i>British Journal of Ophthalmology</i> , 2014, 98, 1636-1641.	2.1	302
437	Intravitreal bevacizumab in the treatment of vasoproliferative retinal tumours. <i>Eye</i> , 2014, 28, 968-973.	1.1	19
438	V.A.5. Surgery of Diabetic Vitreo-Retinopathy and Diabetic Macular Edema. , 2014, , 629-645.		0
440	Intravitreal Injection of Ranibizumab for Treatment of Age-Related Macular Degeneration: Effects on Serum VEGF Concentration. <i>Current Eye Research</i> , 2014, 39, 518-521.	0.7	26
441	Advanced Proliferative Diabetic Retinopathy. , 2014, , 163-178.		0
442	Fourier-domain optical coherence tomography evaluation of retinal and optic nerve head neovascularisation in proliferative diabetic retinopathy. <i>British Journal of Ophthalmology</i> , 2014, 98, 65-72.	2.1	33
443	Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy. <i>Diabetes and Metabolism</i> , 2014, 40, 445-451.	1.4	41
444	The Role of Intraoperative Bevacizumab for Prevention of Postoperative Vitreous Hemorrhage in Diabetic Vitreous Hemorrhage. <i>European Journal of Ophthalmology</i> , 2014, 24, 88-93.	0.7	7
445	EFFECTS OF INTRAVITREAL INJECTION OF BEVACIZUMAB ON INFLAMMATORY CYTOKINES IN THE VITREOUS WITH PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2014, 34, 165-171.	1.0	24

#	ARTICLE	IF	CITATIONS
446	Chapter 9: Proliferative Diabetic Retinopathy. , 2015, , 73-81.		1
447	Angiogenesis and Eye Disease. Annual Review of Vision Science, 2015, 1, 155-184.	2.3	41
448	Local Therapeutic Options for Uveitic Cystoid Macular Edema. International Ophthalmology Clinics, 2015, 55, 39-61.	0.3	1
449	RANDOMIZED CONTROLLED STUDY OF INTRAVITREAL BEVACIZUMAB 0.16 MG INJECTED ONE DAY BEFORE SURGERY FOR PROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2015, 35, 1800-1807.	1.0	17
450	New Therapeutic Approaches in Diabetic Retinopathy. Review of Diabetic Studies, 2015, 12, 196-210.	0.5	28
452	Progression to macula-off tractional retinal detachment after a contralateral intraoperative intravitreal bevacizumab injection for proliferative diabetic retinopathy. Clinical Ophthalmology, 2015, 9, 409.	0.9	4
453	Ocular complications of diabetes mellitus. World Journal of Diabetes, 2015, 6, 92.	1.3	225
454	Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice. PLoS ONE, 2015, 10, e0134308.	1.1	13
455	Progression to macula-off tractional retinal detachment after a contralateral intraoperative intravitreal bevacizumab injection for proliferative diabetic retinopathy. Clinical Ophthalmology, 2015, 9, 69.	0.9	8
456	Assessment of Patient Pain Experience during Intravitreal 27-Gauge Bevacizumab and 30-Gauge Ranibizumab Injection. Korean Journal of Ophthalmology: KJO, 2015, 29, 190.	0.5	22
457	Intravitreal Anti-VEGF Injections in Pregnancy: Case Series and Review of Literature. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 605-610.	0.6	54
458	In Vitro/In Vivo Evaluation of Dexamethasoneâ€™PAMAM Dendrimer Complexes for Retinal Drug Delivery. Journal of Pharmaceutical Sciences, 2015, 104, 3814-3823.	1.6	76
459	Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 287-294.	1.0	28
460	Comparing different dosing regimens of bevacizumab in the treatment of neovascular macular degeneration: study protocol for a randomised controlled trial. Trials, 2015, 16, 85.	0.7	7
461	Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity. Ophthalmology, 2015, 122, 1008-1015.	2.5	179
462	Painless Indirect Argon Laser in High Risk Proliferative Diabetic Retinopathy. Klinische Monatsblätter Fur Augenheilkunde, 2015, 232, 509-513.	0.3	4
463	Effects of intravitreal injection of bevacizumab on nitric oxide levels. Eye, 2015, 29, 436-442.	1.1	5
464	Bevacizumab Revisited: Its Use in Different Mouse Models of Ocular Pathologies. Current Eye Research, 2015, 40, 611-621.	0.7	24

#	ARTICLE	IF	CITATIONS
465	Preliminary Anatomical and Neurodevelopmental Outcomes of Intravitreal Bevacizumab As Adjunctive Treatment for Retinopathy of Prematurity. <i>Current Eye Research</i> , 2015, 40, 585-591.	0.7	46
466	Feasibility of Telemedicine in Detecting Diabetic Retinopathy and Age-Related Macular Degeneration. <i>Seminars in Ophthalmology</i> , 2015, 30, 81-95.	0.8	23
467	New treatments for diabetic retinopathy. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 219-230.	2.2	62
468	Role of bevacizumab in the prevention of early postoperative haemorrhage after 25-gauge microincision vitrectomy surgery. <i>Pakistan Journal of Medical Sciences</i> , 2016, 32, 1184-1187.	0.3	2
469	Regulatory SNPs Alter the Gene Expression of Diabetic Retinopathy Associated Secretary Factors. <i>International Journal of Medical Sciences</i> , 2016, 13, 717-723.	1.1	14
470	Effects of Intravitreal Injection of Bevacizumab or Ranibizumab on Systemic Circulation. <i>Journal of Korean Ophthalmological Society</i> , 2016, 57, 429.	0.0	3
471	Characteristics of Retinal Neovascularization in Proliferative Diabetic Retinopathy Imaged by Optical Coherence Tomography Angiography. , 2016, 57, 6247.		116
472	Intravitreal Ranibizumab Injection as an Adjuvant in the Treatment of Neovascular Glaucoma Accompanied by Vitreous Hemorrhage after Diabetic Vitrectomy. <i>Journal of Ophthalmology</i> , 2016, 2016, 1-7.	0.6	7
473	Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment. <i>PLoS ONE</i> , 2016, 11, e0148019.	1.1	121
474	The outcomes and prognostic factors of vitrectomy in chronic diabetic traction macular detachment. <i>Clinical Ophthalmology</i> , 2016, Volume 10, 1653-1661.	0.9	15
475	Involvement of IL-37 in the Pathogenesis of Proliferative Diabetic Retinopathy. , 2016, 57, 2955.		16
476	Diabetic retinopathy clinical practice guidelines: Customized for Iranian population. <i>Journal of Ophthalmic and Vision Research</i> , 2016, 11, 394.	0.7	10
477	Current and investigational drugs for the treatment of diabetic retinopathy. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1011-1022.	1.9	25
478	Sustained intraocular VEGF neutralization results in retinal neurodegeneration in the <i>Ins2Akita</i> diabetic mouse. <i>Scientific Reports</i> , 2016, 5, 18316.	1.6	54
479	Effect of drug <i>Piper nigrum</i> on magnesium chloride at varying concentration and temperature through ultrasonic method: A thermoacoustic study. <i>Cogent Physics</i> , 2016, 3, .	0.7	0
480	The adjunctive use of pre-operative intravitreal bevacizumab in the setting of proliferative diabetic retinopathy. <i>Saudi Journal of Ophthalmology</i> , 2016, 30, 217-220.	0.3	6
482	Anti-“Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease. <i>Ophthalmology</i> , 2016, 123, S78-S88.	2.5	100
483	Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy. <i>Current Diabetes Reports</i> , 2016, 16, 122.	1.7	24

#	ARTICLE	IF	CITATIONS
484	An Update in the Management of Proliferative Diabetic Retinopathy. <i>International Ophthalmology Clinics</i> , 2016, 56, 209-225.	0.3	3
485	Effects of Combined Photodynamic Therapy and Topical Bevacizumab Treatment on Corneal Neovascularization in Rabbits. <i>Cornea</i> , 2016, 35, 1615-1620.	0.9	14
486	Evaluation of Intravitreal Ranibizumab on the Surgical Outcome for Diabetic Retinopathy With Tractional Retinal Detachment. <i>Medicine (United States)</i> , 2016, 95, e2731.	0.4	11
487	Bevacizumab anticancer monoclonal antibody: native and denatured redox behaviour. <i>Electrochimica Acta</i> , 2016, 206, 246-253.	2.6	17
488	Dimethylarginine dimethylaminohydrolase-2 deficiency promotes vascular regeneration and attenuates pathological angiogenesis. <i>Experimental Eye Research</i> , 2016, 147, 148-155.	1.2	19
489	Ranibizumab for High-Risk Proliferative Diabetic Retinopathy: An Exploratory Randomized Controlled Trial. <i>Ophthalmologica</i> , 2016, 235, 34-41.	1.0	26
490	Surgical Management of Tractional Retinal Detachments in Proliferative Diabetic Retinopathy. <i>Current Ophthalmology Reports</i> , 2016, 4, 75-83.	0.5	0
491	Repositioning Bevacizumab: A Promising Therapeutic Strategy for Cartilage Regeneration. <i>Tissue Engineering - Part B: Reviews</i> , 2016, 22, 341-357.	2.5	8
492	Vascular Endothelial Growth Factor and Diabetic Retinal Disease. <i>Seminars in Ophthalmology</i> , 2016, 31, 40-48.	0.8	44
493	Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age-related macular degeneration and diabetic macular edema. <i>International Ophthalmology</i> , 2017, 37, 147-158.	0.6	10
494	High-precision, non-invasive anti-microvascular approach via concurrent ultrasound and laser irradiation. <i>Scientific Reports</i> , 2017, 7, 40243.	1.6	27
495	Silencing of galectin-1 inhibits retinal neovascularization and ameliorates retinal hypoxia in a murine model of oxygen-induced ischemic retinopathy. <i>Experimental Eye Research</i> , 2017, 159, 1-15.	1.2	18
496	Surgical Management and Techniques. <i>Developments in Ophthalmology</i> , 2017, 60, 143-159.	0.1	2
497	Suppression of Retinal Neovascularization by Anti-CCR3 Treatment in an Oxygen-Induced Retinopathy Model in Mice. <i>Ophthalmic Research</i> , 2017, 58, 56-66.	1.0	3
498	Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma. <i>Advances in Therapy</i> , 2017, 34, 378-395.	1.3	37
499	Norrin treatment improves ganglion cell survival in an oxygen-induced retinopathy model of retinal ischemia. <i>Experimental Eye Research</i> , 2017, 164, 129-138.	1.2	19
500	Evaluation of the clinical effectiveness of fluocinolone acetonide 190µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. <i>Current Medical Research and Opinion</i> , 2017, 33, 19-31.	0.9	14
501	Preoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: A Randomized and Controlled Trial Comparing Interval Variation. <i>American Journal of Ophthalmology</i> , 2017, 183, 1-10.	1.7	42

#	ARTICLE	IF	CITATIONS
502	Comparison of Topical Low-Molecular-Weight Heparinâ€“Taurocholate and Bevacizumab for Treatment and Prevention of Corneal Neovascularization. <i>Cornea</i> , 2017, 36, 497-501.	0.9	3
503	Evidence-Based Treatment of Diabetic Retinopathy. <i>Seminars in Ophthalmology</i> , 2017, 32, 67-74.	0.8	49
504	Diabetic Microvascular Disease: An Endocrine Society Scientific Statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4343-4410.	1.8	323
505	Evaluation of effect of bevacizumab on central subfield macular thickness in the injected and contralateral (untreated) eye of patients with bilateral diabetic macular oedema. <i>BMJ Open Ophthalmology</i> , 2017, 2, e000102.	0.8	3
506	Efficacy of intravitreal bevacizumab combined with pan retinal photocoagulation versus panretinal photocoagulation alone in treatment of proliferative diabetic retinopathy. <i>Pakistan Journal of Medical Sciences</i> , 2017, 33, 142-145.	0.3	13
507	Suppression of Retinal Neovascularization by Inhibition of Galectin-1 in a Murine Model of Oxygen-Induced Retinopathy. <i>Journal of Ophthalmology</i> , 2017, 2017, 1-12.	0.6	7
508	Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. <i>JCI Insight</i> , 2017, 2, .	2.3	662
509	Vitreous Fibronectin and Fibrinogen Expression Increased in Eyes With Proliferative Diabetic Retinopathy After Intravitreal Anti-VEGF Therapy. , 2017, 58, 5783.		28
510	The Choroid in Retinal Vascular Diseases. , 2017, , 289-305.		1
511	Observation of optic disc neovascularization using OCT angiography in proliferative diabetic retinopathy after intravitreal conbercept injections. <i>Scientific Reports</i> , 2018, 8, 3972.	1.6	20
512	The role of autophagy in ageâ€“related macular degeneration. <i>Acta Ophthalmologica</i> , 2018, 96, 1-50.	0.6	10
513	Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study). <i>Ophthalmology</i> , 2018, 125, 691-700.	2.5	84
514	BIMANUAL MICROINCISION VITREOUS SURGERY FOR SEVERE PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2018, 38, S134-S145.	1.0	18
515	Ranibizumab-induced retinal reperfusion and regression of neovascularization in diabetic retinopathy: An angiographic illustration. <i>American Journal of Ophthalmology Case Reports</i> , 2018, 9, 41-44.	0.4	23
516	The association between myocardial infarction and intravitreal bevacizumab injection. <i>Medicine (United States)</i> , 2018, 97, e0198.	0.4	8
517	Evaluation of vitreous levels of advanced glycation end products and angiogenic factors as biomarkers for severity of diabetic retinopathy. <i>International Ophthalmology</i> , 2018, 38, 607-615.	0.6	32
518	Pathophysiology, screening and treatment of ROP: A multi-disciplinary perspective. <i>Progress in Retinal and Eye Research</i> , 2018, 62, 77-119.	7.3	109
520	Advanced proliferative diabetic retinopathy during pregnancy. <i>Journal Francais D'Ophtalmologie</i> , 2018, 41, e485-e487.	0.2	3

#	ARTICLE	IF	CITATIONS
521	Editorial on photoreceptor glucose metabolism determines normal retinal vascular growth. <i>Annals of Eye Science</i> , 2018, 3, 14-14.	1.1	0
522	Functional Characterization of Abicipar-Pegol, an Anti-VEGF DARPIn Therapeutic That Potently Inhibits Angiogenesis and Vascular Permeability. , 2018, 59, 5836.		61
523	Bevacizumab before Diabetic Vitrectomy. <i>Ophthalmology Retina</i> , 2018, 2, 1010-1020.	1.2	10
524	Anti-VEGF Vascular Endothelial Growth Factor Drugs to Reduce Diabetic Retinopathy Progression. <i>Ophthalmology Retina</i> , 2018, 2, 985-987.	1.2	1
525	Repurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization. <i>PLoS ONE</i> , 2018, 13, e0202436.	1.1	11
526	ISL1 is upregulated in breast cancer and promotes cell proliferation, invasion, and angiogenesis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 781-789.	1.0	19
527	Self-Assembly of an Antiangiogenic Nanofibrous Peptide Hydrogel. <i>ACS Applied Bio Materials</i> , 2018, 1, 865-870.	2.3	31
528	Intravitreal Bevacizumab Injection Attenuates Diabetic Retinopathy in Adult Rats with Experimentally Induced Diabetes in the Early Stage. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-18.	1.0	9
529	Pars plana vitrectomy in vitreous hemorrhage with or without Intravitreal Bevacizumab a comparative overview. <i>Pakistan Journal of Medical Sciences</i> , 2018, 34, 221-225.	0.3	9
530	Role of oxidative stress, inflammation, hypoxia and angiogenesis in the development of diabetic retinopathy. <i>Saudi Journal of Ophthalmology</i> , 2018, 32, 318-323.	0.3	93
531	An Overview of Diabetic Retinopathy. , 2018, , 139-154.		0
532	Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy. <i>Ophthalmology</i> , 2018, 125, 1776-1783.	2.5	25
533	Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review. <i>Journal of Ophthalmology</i> , 2018, 2018, 1-13.	0.6	32
534	Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy. <i>Journal of Ophthalmology</i> , 2018, 2018, 1-11.	0.6	15
535	Diabetes and the Eye. <i>Endocrinology</i> , 2018, , 1-44.	0.1	0
536	Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients With Age-Related Macular Degeneration Treated With Intravitreal Aflibercept or Ranibizumab. <i>JAMA Ophthalmology</i> , 2019, 137, 914.	1.4	29
537	Overt Proteinuria, Moderately Reduced eGFR and Their Combination Are Predictive of Severe Diabetic Retinopathy or Diabetic Macular Edema in Diabetes. , 2019, 60, 2685.		18
538	Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy. <i>Ophthalmology Retina</i> , 2019, 3, 1076-1086.	1.2	47

#	ARTICLE	IF	CITATIONS
539	Expression of vascular infarction-related molecules after anti-vascular endothelium growth factor treatment for diabetic macular edema. <i>Scientific Reports</i> , 2019, 9, 12373.	1.6	5
540	Branch retinal artery occlusion in the untreated contralateral eye following aflibercept injections during heparin treatment: Possible contribution of a heparin-induced thrombocytopenia-like condition. <i>American Journal of Ophthalmology Case Reports</i> , 2019, 16, 100549.	0.4	1
541	OCT angiography-based monitoring of neovascular regression on fibrovascular membrane after preoperative intravitreal conbercept injection. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2019, 257, 1611-1619.	1.0	20
542	Intravitreal bevacizumab versus ranibizumab: Effects on the vessels of the fellow non-treated eye. <i>Journal of Current Ophthalmology</i> , 2019, 31, 55-60.	0.3	7
543	Pulse Pressure is a Stronger Predictor Than Systolic Blood Pressure for Severe Eye Diseases in Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2019, 8, e010627.	1.6	18
544	Incidence and Risk Factors for Tractional Macular Detachment after Anti-Vascular Endothelial Growth Factor Agent Pretreatment before Vitrectomy for Complicated Proliferative Diabetic Retinopathy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1960.	1.0	11
545	Management of Retinopathy of Prematurity—Use of Anti-VEGF Therapy. <i>Asia-Pacific Journal of Ophthalmology</i> , 2019, 7, 56-62.	1.3	23
546	Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor. <i>Ophthalmology</i> , 2019, 126, 407-413.	2.5	109
547	Which quadrant is less painful for intravitreal injection? A prospective study. <i>Eye</i> , 2019, 33, 304-312.	1.1	6
548	Preclinical Evaluation of ADVN-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration. <i>Molecular Therapy</i> , 2019, 27, 118-129.	3.7	83
550	Effects of intravitreal bevacizumab in Gram-positive and Gram-negative models of ocular inflammation. <i>Clinical and Experimental Ophthalmology</i> , 2019, 47, 638-645.	1.3	9
551	Proliferative Diabetic Retinopathy. , 2019, , 185-246.		0
552	APOPTOSIS AND ANGIOFIBROSIS IN DIABETIC TRACTIONAL MEMBRANES AFTER VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION. <i>Retina</i> , 2019, 39, 265-273.	1.0	18
553	TIME COURSE OF CHANGES IN OPTIC DISK NEOVASCULARIZATION AFTER A SINGLE INTRAVITREAL BEVACIZUMAB INJECTION. <i>Retina</i> , 2019, 39, 1149-1153.	1.0	11
554	Effect of elevation of vascular endothelial growth factor level on exacerbation of hemorrhage in mouse brain arteriovenous malformation. <i>Journal of Neurosurgery</i> , 2020, 132, 1566-1573.	0.9	27
555	The Short-Term Efficacy of Biweekly Subconjunctival Bevacizumab in Diabetic Macular Edema. <i>Current Eye Research</i> , 2020, 45, 585-590.	0.7	1
556	Patient perceived value of teleophthalmology in an urban, low income US population with diabetes. <i>PLoS ONE</i> , 2020, 15, e0225300.	1.1	31
557	Proliferative diabetic retinopathy as onset of type 1 diabetes. <i>Canadian Journal of Ophthalmology</i> , 2020, 55, e92-e95.	0.4	0

#	ARTICLE	IF	CITATIONS
558	ANTI-VEGF VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2020, 40, 1021-1028.	1.0	21
559	3D printing of drug-loaded multi-shell rods for local delivery of bevacizumab and dexamethasone: A synergetic therapy for retinal vascular diseases. <i>Acta Biomaterialia</i> , 2020, 116, 174-185.	4.1	48
560	Lipid Keratopathy: A Review of Pathophysiology, Differential Diagnosis, and Management. <i>Ophthalmology and Therapy</i> , 2020, 9, 833-852.	1.0	19
561	Effect of Intravitreal Injections on Retinal Imaging Metrics in Glaucomatous and Non-Glaucomatous Eyes. <i>Current Ophthalmology Reports</i> , 2020, 8, 111-119.	0.5	5
562	Dual-Acting Antiangiogenic Gene Therapy Reduces Inflammation and Regresses Neovascularization in Diabetic Mouse Retina. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 22, 329-339.	2.3	6
563	The long-term effects of anti-vascular endothelial growth factor therapy on the optical coherence tomography angiographic appearance of neovascularization in age-related macular degeneration. <i>International Journal of Retina and Vitreous</i> , 2020, 6, 39.	0.9	13
564	Formulation of nanoliposome-encapsulated bevacizumab (Avastin): Statistical optimization for enhanced drug encapsulation and properties evaluation. <i>International Journal of Pharmaceutics</i> , 2020, 590, 119895.	2.6	12
565	Neutrophil extracellular traps target senescent vasculature for tissue remodeling in retinopathy. <i>Science</i> , 2020, 369, .	6.0	139
566	Identification of NLRP3 Inflammation-Related Gene Promoter Hypomethylation in Diabetic Retinopathy. , 2020, 61, 12.		8
567	Efficacy and safety of Chinese medicines for vitreous hemorrhage. <i>Medicine (United States)</i> , 2020, 99, e20086.	0.4	0
568	Lutein and zeaxanthin attenuates VEGF-induced neovascularisation in human retinal microvascular endothelial cells through a Nox4-dependent pathway. <i>Experimental Eye Research</i> , 2020, 197, 108104.	1.2	16
569	Microfluidic Immunosensor for Point-of-Care-Testing of Beta-2-Microglobulin in Tear. <i>ACS Sustainable Chemistry and Engineering</i> , 2020, 8, 9268-9276.	3.2	15
570	Update in the Treatment of Retinopathy of Prematurity. <i>American Journal of Perinatology</i> , 2022, 39, 022-030.	0.6	17
571	Comparison of aqueous humor levels of PIGF and VEGF in proliferative diabetic retinopathy before and after intravitreal conbercept injection. <i>Diabetes Research and Clinical Practice</i> , 2020, 162, 108083.	1.1	15
572	Do Genomic Factors Play a Role in Diabetic Retinopathy?. <i>Journal of Clinical Medicine</i> , 2020, 9, 216.	1.0	28
573	The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study. <i>BMC Ophthalmology</i> , 2020, 20, 43.	0.6	11
574	Implantable anti-angiogenic scaffolds for treatment of neovascular ocular pathologies. <i>Drug Delivery and Translational Research</i> , 2020, 10, 1191-1202.	3.0	6
575	Genotypes and Phenotypes: A Search for Influential Genes in Diabetic Retinopathy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2712.	1.8	20

#	ARTICLE	IF	CITATIONS
576	Bacterial contamination of intravitreal needles by the ocular surface microbiome. <i>Ocular Surface</i> , 2021, 19, 169-175.	2.2	8
577	Drugs Used in Ophthalmology. , 2021, , 413-499.		0
578	Non-invasive multimodal imaging of Diabetic Retinopathy: A survey on treatment methods and Nanotheranostics. <i>Nanotheranostics</i> , 2021, 5, 166-181.	2.7	5
579	Intravitreal injection of ranibizumab (Lucentis) versus pan-retinal photocoagulation as a preoperative adjuvant before vitrectomy in management of proliferative diabetic retinopathy. <i>Journal of Medicine in Scientific Research</i> , 2021, 4, 63.	0.0	0
580	Comparative study of the efficacy of bevacizumab and rose bengal photodynamic therapy for treatment of corneal neovascularization. <i>Archives of Medical Science - Civilization Diseases</i> , 2021, 6, 22-30.	0.1	0
581	Effect of intravitreal bevacizumab in the uninjected fellow eye of patients treated for retinal disorders. <i>Indian Journal of Clinical and Experimental Ophthalmology</i> , 2021, 7, 234-239.	0.1	0
582	From the Hypotheses to Clinical Evidence in Retinal Therapy. <i>Journal of Ophthalmic and Vision Research</i> , 2021, 16, 287-290.	0.7	0
583	Intravitreal bevacizumab (IVB) versus IVB in combination with pars plana vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy: a randomized clinical trial. <i>International Journal of Retina and Vitreous</i> , 2021, 7, 35.	0.9	4
584	Role of bevacizumab intraocular injection in the management of neovascular glaucoma. <i>International Journal of Ophthalmology</i> , 2021, 14, 855-859.	0.5	1
585	Recent trends in drug-delivery systems for the treatment of diabetic retinopathy and associated fibrosis. <i>Advanced Drug Delivery Reviews</i> , 2021, 173, 439-460.	6.6	25
586	Rates of RNFL Thinning in Patients with Suspected or Confirmed Glaucoma Receiving Unilateral Intravitreal Injections for Exudative AMD. <i>American Journal of Ophthalmology</i> , 2021, 226, 206-216.	1.7	9
589	Inhibition of APE1/Ref-1 for Neovascular Eye Diseases: From Biology to Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10279.	1.8	16
590	Reply. <i>Retina</i> , 2021, 41, e65-e66.	1.0	0
591	ASSESSMENT OF INTRAOCULAR PRESSURE FOLLOWING THE INTRAVITREAL INJECTION OF ANTI-VEGF. <i>International Journal of Current Pharmaceutical Research</i> , 0, , 52-55.	0.2	0
592	Effect of Intravitreal Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2383.	3.8	70
593	The Relationship of Diabetic Retinopathy and Glaucoma. , 2010, , 325-346.		3
594	Treatment of Proliferative Diabetic Retinopathy. , 2010, , 227-304.		4
595	Retinopathy in Diabetes. <i>Advances in Experimental Medicine and Biology</i> , 2013, 771, 88-106.	0.8	33

#	ARTICLE	IF	CITATIONS
597	Beyond VEGF – Other Factors Important in Retinal Neovascularization: Potential Targets in Proliferative Diabetic Retinopathy. , 2008, , 375-398.		2
598	Mass Transport via Cellular Barriers and Endocytosis. <i>Fundamental Biomedical Technologies</i> , 2011, , 3-55.	0.2	4
599	INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH OR WITHOUT PRIOR TREATMENT WITH PHOTODYNAMIC THERAPY. <i>Retina</i> , 2010, 30, 85-92.	1.0	15
600	Hypoxia-inducible factors and diabetes. <i>Journal of Clinical Investigation</i> , 2020, 130, 5063-5073.	3.9	84
601	The Angio-Fibrotic Switch of VEGF and CTGF in Proliferative Diabetic Retinopathy. <i>PLoS ONE</i> , 2008, 3, e2675.	1.1	197
602	PEDF Regulates Vascular Permeability by a β 3-Secretase-Mediated Pathway. <i>PLoS ONE</i> , 2011, 6, e21164.	1.1	60
603	Mechanisms Controlling the Effects of Bevacizumab (Avastin) on the Inhibition of Early but Not Late Formed Corneal Neovascularization. <i>PLoS ONE</i> , 2014, 9, e94205.	1.1	37
604	Improvement of Diabetic Macular Edema in the Fellow Eye After Monocular Intravitreal Bevacizumab Injection. <i>Hospital Practices and Research</i> , 2017, 2, 54-55.	0.1	2
605	Endoplasmic reticulum stress and diabetic retinopathy. <i>Vascular Health and Risk Management</i> , 2008, 4, 115-122.	1.0	66
606	Diabetic Retinopathy: Understanding Pathologic Angiogenesis and Exploring its Treatment Options. <i>The Open Circulation & Vascular Journal</i> , 2012, 3, 30-42.	0.4	5
607	Outcome of a Single Intravitreal Bevacizumab Injection on the Visual Acuity and Course of Pars Plana Vitrectomy in Proliferative Diabetic Retinopathy. <i>Current Eye Research</i> , 2013, , 1-6.	0.7	2
608	Influence of unilateral intravitreal bevacizumab injection on the incidence of symptomatic choroidal neovascularization in the fellow eye in patients with neovascular age-related macular degeneration (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	0.8	5
609	Intravitreal Anti-VEGF Therapy as a Treatment for Retinopathy of Prematurity: What We Know After 7 Years. <i>Journal of Pediatric Ophthalmology and Strabismus</i> , 2015, 52, 77-84.	0.3	40
610	Intravitreal Bevacizumab in Aggressive Posterior Retinopathy of Prematurity. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2007, 38, 233-237.	0.4	132
611	Acute Visual Acuity Loss Following Intravitreal Bevacizumab for Diabetic Macular Edema. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2009, 40, 68-70.	0.4	37
612	Ghost Cell Glaucoma After Intravitreal Bevacizumab for Postoperative Vitreous Hemorrhage Following Vitrectomy for Proliferative Diabetic Retinopathy. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2010, 41, 72-77.	0.4	10
613	The Relation Between Bevacizumab Injection and the Formation of Subretinal Fibrosis in Diabetic Patients With Panretinal Photocoagulation. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2010, 41, 190-195.	0.4	17
614	Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy. <i>Ophthalmic Surgery, Lasers and Imaging</i> , 2010, , 1-3.	0.5	5

#	ARTICLE	IF	CITATIONS
615	Acute Anterior Uveitis Following Intravitreal Injection of Bevacizumab. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2013, 44, 25-27.	0.4	18
616	The Effect of Bevacizumab Pretreatment on the Choice of Endotamponade in Diabetic Tractional Retinal Detachment. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2016, 47, 924-929.	0.4	6
617	Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits. <i>International Journal of Ophthalmology</i> , 2015, 8, 653-8.	0.5	22
618	Current trends in the pharmacotherapy of diabetic retinopathy. <i>Journal of Postgraduate Medicine</i> , 2012, 58, 132-139.	0.2	46
619	Batch-related sterile endophthalmitis following intravitreal injection of bevacizumab. <i>Indian Journal of Ophthalmology</i> , 2014, 62, 468.	0.5	15
620	Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?. <i>Indian Journal of Ophthalmology</i> , 2016, 64, 4.	0.5	21
621	Bevacizumab: Off-label use in ophthalmology. <i>Indian Journal of Ophthalmology</i> , 2007, 55, 417.	0.5	58
622	The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice. <i>Indian Journal of Ophthalmology</i> , 2007, 55, 445.	0.5	19
623	Intra-cameral injection of Bevacizumab (Avastin) to treat anterior chamber neovascular membrane in a painful blind eye. <i>Indian Journal of Ophthalmology</i> , 2008, 56, 258.	0.5	5
624	The effect of intravitreal bevacizumab and ranibizumab on macular edema of the contralateral eye: A comparative study of two anti-VEGFs. <i>Oman Journal of Ophthalmology</i> , 2016, 9, 44.	0.2	8
625	Changes in retinal nerve fiber layer thickness after two intravitreal bevacizumab injections for wet type age-related macular degeneration. <i>Journal of Ophthalmic and Vision Research</i> , 2014, 9, 449.	0.7	11
626	Cataract surgery in diabetes mellitus: A systematic review. <i>Indian Journal of Ophthalmology</i> , 2018, 66, 1401.	0.5	44
627	Efficacy of intravitreal bevacizumab for the treatment of Zone I Type 1 retinopathy of prematurity. <i>Journal of Ophthalmic and Vision Research</i> , 2018, 13, 29.	0.7	8
628	Lamellar macular hole formation following intravitreal bevacizumab injection for choroidal neovascularization by age-related macular degeneration. <i>Oman Journal of Ophthalmology</i> , 2018, 11, 277.	0.2	2
629	Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm?. <i>Taiwan Journal of Ophthalmology</i> , 2019, 9, 216.	0.3	10
630	The Efficacy of Intravitreal Bevacizumab in Vitreous Hemorrhage of Diabetic Subjects. <i>Türk Oftalmoloji Dergisi</i> , 2016, 46, 221-225.	0.4	8
631	Bilateral Regression of Choroidal Neovascularization Associated with Pathologic Myopia following Unilateral Intravitreal Bevacizumab Injection. <i>World Journal of Retina and Vitreous</i> , 2011, 1, 23-26.	0.0	2
632	Intravitreal Injections of Bevacizumab: The Impact of Needle Size in Intraocular Pressure and Pain. <i>Journal of Current Glaucoma Practice</i> , 2017, 11, 38-41.	0.1	12

#	ARTICLE	IF	CITATIONS
633	Efficacy of Simultaneous Usage of Bevacizumab and Silicone Oil Injection After Vitrectomy in Diabetic Tractional Retinal Detachment. <i>Razavi International Journal of Medicine</i> , 2016, 5, .	0.1	1
634	The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy. <i>Drugs in Context</i> , 2018, 7, 1-10.	1.0	108
635	Pharmacotherapy of Diabetic Retinopathy. , 2007, , 255-260.		1
636	Antagonism of the Growth Hormone Axis as a Therapeutic Strategy for Diabetic Retinopathy. , 2008, , 449-463.		0
637	Anti-VEGF Therapy as an Emerging Treatment for Diabetic Retinopathy. , 2008, , 401-422.		0
638	Diagnosis, Management, and Treatment of Nonproliferative Diabetic Retinopathy. , 2008, , 1775-1791.		1
640	Glaucomas: Neovascular Glaucoma. , 2010, , 379-387.		0
642	Vitrectomía en Pacientes Diabéticos con Glaucoma Neovascular. <i>Highlights of Vitreoretina</i> , 2010, 2, 4-7.	0.0	0
643	INTRAVITREAL BEVACIZUMAB FOR PREVENTION OF EARLY POSTVITRECTOMY HEMORRHAGE IN DIABETIC PATIENTS. <i>Evidence-Based Ophthalmology</i> , 2010, 11, 48-49.	0.0	0
644	Traitement de la rétinopathie diabétique. , 2010, , 111-141.		0
645	Anti-VEGF en combinaci3n con fotocoagulaci3n láser. , 2010, , 61-64.		0
646	Clinical Examples in Managing Diabetic Retinopathy. , 2010, , 403-439.		0
647	Anti-VEGF en retinopatía diabética proliferativa. , 2010, , 115-120.		0
649	Diabete. , 2011, , 375-388.		0
650	Laser/Light Applications in Ophthalmology: Posterior Segment Applications. , 2011, , 435-446.		0
651	Pattern of Presentation of Sickle Cell Retinopathy in Ibadan. <i>Journal of Clinical & Experimental Ophthalmology</i> , 2012, 03, .	0.1	0
653	Acute Anterior Uveitis Following Intravitreal Injection of Bevacizumab. <i>Ophthalmic Surgery, Lasers and Imaging</i> , 0, , .	0.5	0
654	Bone Marrow Stem Cells in Retinal Disease. , 2013, , 99-105.		0

#	ARTICLE	IF	CITATIONS
655	Vasculogenesis and angiogenesis in diabetes mellitus: novel pathogenetic concepts for treatment of vascular complications. <i>Diabetes Mellitus</i> , 2012, 15, 17-27.	0.5	5
656	The surgical management of diabetic retinopathy complications: An update. <i>Egyptian Retina Journal</i> , 2014, 2, 41.	0.2	1
657	Visual Outcome versus Vision Satisfaction after Intravitreal Bevasizumb Injection in Diabetic Retinopathy. <i>Ophthalmology Research an International Journal</i> , 2014, 2, 352-360.	0.1	0
658	Preoperative intravitreal bevacizumab and silicone oil tamponade for vitrectomy in diabetic retinopathy. <i>World Journal of Ophthalmology</i> , 2014, 4, 75.	0.1	0
659	Drug-induced ocular side effects. , 2015, , 47-343.		0
660	Evaluaci3n y Manejo del Edema Macular Diab3tico. <i>Highlights of Vitreoretina</i> , 2015, 8, 2-12.	0.0	0
661	Influence of Intravitreal Bevacizumab Therapy on the Patterns of Diabetic Maculopathy on Optical Coherence Tomography. <i>Bahrain Medical Bulletin</i> , 2015, 37, 105-108.	0.1	0
662	Glaucomas: Neovascular Glaucoma. , 2016, , 457-469.		0
663	Efficacy of Simultaneous Usage of Bevacizumab and Silicone Oil Injection After Vitrectomy in Diabetic Tractional Retinal Detachment. <i>Razavi International Journal of Medicine</i> , 2016, In Press, .	0.1	0
664	Intravitreal bevacizumab alone or combined with macular laser for treatment of diabetic macular edema. <i>Egyptian Retina Journal</i> , 2017, 4, 37.	0.2	0
665	Indications and treatment outcomes of intravitreal bevacizumab and ranibizumab for retinal diseases in Benin City, Nigeria. <i>Journal of the Nigerian Mathematical Society</i> , 2017, 25, 14.	0.1	2
666	Post-traumatic Uveitis and Post-operative Inflammation. , 2017, , 275-284.		1
667	Acute Disturbance/Loss of Vision. <i>Ocular Trauma</i> , 2018, , 57-94.	0.1	0
668	Rapid regression of retinal neovascularization following intravitreal bevacizumab in branch retinal vein occlusion imaged by optical coherence tomography angiography. <i>Indian Journal of Ophthalmology</i> , 2018, 66, 572.	0.5	1
669	Diabetes and the Eye. <i>Endocrinology</i> , 2018, , 231-273.	0.1	0
670	Laser/Light Applications in Ophthalmology: Posterior Segment Applications. , 2018, , 17-32.		0
671	Adjunctive Intravitreal Bevacizumab with Vitrectomy for Diabetic Vitreous Hemorrhage. <i>The Egyptian Journal of Hospital Medicine</i> , 2018, 72, 5144-5152.	0.0	0
672	Diabetes and the Eye. <i>Endocrinology</i> , 2019, , 1-43.	0.1	0

#	ARTICLE	IF	CITATIONS
673	Bevacizumab in Wet AMD treatment: A tribute to the thirteen years of experience from the beginning of the anti-VEGF era in Romania. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 4993-5000.	0.8	15
674	TANDEM TRIAL: a factorial randomised controlled trial of dose and review schedule of bevacizumab (Avastin) for neovascular macular degeneration in the East Midlands. <i>BMJ Open Ophthalmology</i> , 2020, 5, e000588.	0.8	0
675	Diabetes and the Eye. <i>Endocrinology</i> , 2020, , 231-273.	0.1	0
676	Anti-VEGF Treatment for Age-Related Macular Degeneration. , 2007, , 53-66.		0
677	Diabetic Vitrectomy. , 0, , .		1
678	Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications. <i>Vascular Health and Risk Management</i> , 2007, 3, 823-32.	1.0	33
679	Intravitreal bevacizumab: an analysis of the evidence. <i>Clinical Ophthalmology</i> , 2007, 1, 273-84.	0.9	8
680	Mini drug pump for ophthalmic use. <i>Transactions of the American Ophthalmological Society</i> , 2009, 107, 60-70.	1.4	24
681	Novel Pharmacologic Approaches for the Management of Diabetic Retinopathy. <i>Molecular and Cellular Pharmacology</i> , 2009, 1, 222-227.	1.7	2
682	Topical application of recombinant calreticulin peptide, vasostatin 48, alleviates laser-induced choroidal neovascularization in rats. <i>Molecular Vision</i> , 2010, 16, 756-67.	1.1	10
683	Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1 α . <i>Molecular Vision</i> , 2012, 18, 1-9.	1.1	20
684	Effect of intravitreal bevacizumab injection before vitrectomy on proliferative diabetic retinopathy. <i>International Journal of Ophthalmology</i> , 2010, 3, 261-3.	0.5	4
685	Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration. <i>Molecular Vision</i> , 2012, 18, 2578-85.	1.1	20
686	Cataracts in diabetic patients: a review article. <i>Journal of Ophthalmic and Vision Research</i> , 2008, 3, 52-65.	0.7	55
687	Intravitreal bevacizumab as anti-vascular endothelial growth factor in the management of complications of proliferative diabetic retinopathy. <i>Medical Hypothesis, Discovery, and Innovation in Ophthalmology</i> , 2013, 2, 20-4.	0.4	10
688	Apelin in epiretinal membranes of patients with proliferative diabetic retinopathy. <i>Molecular Vision</i> , 2014, 20, 1122-31.	1.1	8
689	Comparison of intravitreal bevacizumab and triamcinolone acetonide therapies for diffuse diabetic macular edema. <i>International Journal of Ophthalmology</i> , 2015, 8, 550-5.	0.5	6
690	Characterization of cells from patient-derived fibrovascular membranes in proliferative diabetic retinopathy. <i>Molecular Vision</i> , 2015, 21, 673-87.	1.1	10

#	ARTICLE	IF	CITATIONS
691	Programmed Death 1 (PD-1) is involved in the development of proliferative diabetic retinopathy by mediating activation-induced apoptosis. <i>Molecular Vision</i> , 2015, 21, 901-10.	1.1	5
692	Role of endogenous insulin gene enhancer protein ISL-1 in angiogenesis. <i>Molecular Vision</i> , 2016, 22, 1375-1386.	1.1	5
693	Potential of Gene Editing and Induced Pluripotent Stem Cells (iPSCs) in Treatment of Retinal Diseases. <i>Yale Journal of Biology and Medicine</i> , 2017, 90, 635-642.	0.2	9
694	Effect of sustained-release long-acting intravitreal dexamethasone implant in patients of non-proliferative diabetic retinopathy undergoing phacoemulsification: A randomized controlled trial. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3263.	0.5	3
695	Feasibility of Therapeutic Ultrasound Application in Topical Scleral Delivery of Avastin. <i>Translational Vision Science and Technology</i> , 2021, 10, 2.	1.1	6
696	Intravitreal bevacizumab prior to vitrectomy for proliferative diabetic retinopathy: a systematic review. <i>Therapeutic Advances in Ophthalmology</i> , 2021, 13, 251584142110592.	0.8	2
697	Angiographic Smokestack Leakage not Associated with Central Serous Chorioretinopathy. <i>Retinal Cases and Brief Reports</i> , 2020, Publish Ahead of Print, .	0.3	0
698	The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage. <i>BMC Ophthalmology</i> , 2022, 22, 63.	0.6	10
702	Medical Versus Surgical Management of Proliferative Diabetic Retinopathy: A Review of Current Treatments, Efficacy, Cost-effectiveness, and Compliance-related Outcomes. <i>International Ophthalmology Clinics</i> , 2022, 62, 3-16.	0.3	0
703	Systemic side effects of ocular medication: Intravitreal and intravenous drugs – part 3. <i>The Optician</i> , 2020, 2020, 8320-1.	0.0	0
704	Molecular mechanism of VEGF and its role in pathological angiogenesis. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 1938-1965.	1.2	30
705	Anti-Vascular Endothelial Growth Factor for Neovascular Glaucoma. <i>Essentials in Ophthalmology</i> , 2022, , 121-130.	0.0	0
706	Inadvertent Use of Bevacizumab to Treat Choroidal Neovascularisation During Pregnancy: A Case Report. <i>Annals of the Academy of Medicine, Singapore</i> , 2010, 39, 143-145.	0.2	34
707	The Role of Inflammation and Therapeutic Concepts in Diabetic Retinopathy – A Short Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1024.	1.8	16
708	Effects on the Contralateral Eye After Intravitreal Bevacizumab and Ranibizumab Injections: A Case Report. <i>Annals of the Academy of Medicine, Singapore</i> , 2008, 37, 591-593.	0.2	43
709	Chronic ocular small vessel disease: An overview of diabetic retinopathy and its relationship with cardiovascular health. <i>American Heart Journal Plus</i> , 2023, 29, 100270.	0.3	1
710	Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	3
711	Pre-operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: the Alvaro Rodriguez lecture 2023. <i>International Journal of Retina and Vitreous</i> , 2023, 9, .	0.9	0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------